NATIONAL CANCER POLICY FORUM

Innovative Person-Centered Clinical Cancer Research

Convened by the National Cancer Policy Forum in collaboration with the Forum on Drug Discovery, Development, and Translation



Keck Center – Keck 100
500 5th St, NW
Washington, DC 20001

Link to view the live webcast:
Innovative Person-Centered Clinical Cancer Research | National Academies

NATIONAL ACADEMIES Sciences Engineering Medicine

NATIONAL CANCER POLICY FORUM

Workshop Location

Keck Center
500 Fifth St., N.W.
Washington, DC 20001

Parking: Entrance to the building's parking garage is in the rear of the building on 6th Street. When entering, be ready to present your identification card and tell the guard the name of the meeting you are attending.

By Metro's Green or Yellow Line

Take Metro's Green or Yellow Line to the Gallery Place-Chinatown station.
Exit the station by following signs to Seventh and F Streets/Arena.
Turn LEFT and walk EAST on F St. N.W., two blocks past the Capital One Arena.
Turn RIGHT on to Fifth St. N.W.
Walk past the fire station parking lot. The next building on your RIGHT will be 500 Fifth St. N.W.

By Metro's Red Line

Take Metro's Red Line to the Judiciary Square station.
Exit the station by following signs to the Building Museum (F St.) exit, between Fourth and Fifth Sts. N.W.
Turn LEFT and walk WEST on F St. N.W.
Cross Fifth St. N.W. and turn LEFT.
Walk past the fire station parking lot. The next building on your RIGHT will be 500 Fifth St. N.W.

NATIONAL CANCER POLICY FORUM

Meeting Location

Innovative Person-Centered Clinical Cancer Research: A Workshop
Room 100



The Workshop on Innovative Person-Centered Clinical Cancer Research will take place in **Room 100**.
The **Keck Cafeteria** is located on the **3rd floor** in the atrium.

NATIONAL CANCER POLICY FORUM

September 29, 2025

Dear Colleagues,

Welcome to the National Academies of Sciences, Engineering, and Medicine workshop on *Innovative Person-Centered Clinical Cancer Research*, convened by the National Cancer Policy Forum in collaboration with the Forum on Drug Discovery, Development, and Translation.

This workshop will examine the challenges in enabling clinical cancer research and explore opportunities to overcome these challenges; discuss potential strategies to embed person-centered principles across the design and conduct of clinical cancer research; and examine the challenges and opportunities to routinely collect, report, and act on patient-reported outcome measures in clinical cancer research. We will also discuss potential strategies to support the oversight and regulation of novel person-centered clinical research methods and to expand the availability of clinical cancer research to patients.

Please note that it is essential to the National Academies mission of providing evidence-based advice that participants in all our activities avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our activities are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academies.

We welcome your involvement in the workshop. Please use the microphones in the room or the chat box on our website to ask questions. Also, please mention your name and affiliation and keep your questions or comments very brief. A proceedings-in-brief from the workshop will be published by the National Academies Press and may incorporate your comments and ideas. Archived presentations and videos from the workshop will also be available on the website.

We look forward to your involvement in this workshop.

Sincerely,

Lawrence N. Shulman
Planning Committee Co-chair
Professor of Medicine
Abramson Cancer Center
University of Pennsylvania

Gwen Darien
Planning Committee Co-chair
Executive Vice President
Patient Advocacy, Engagement and Education
Patient Advocate Foundation

NATIONAL CANCER POLICY FORUM

Innovative Person-Centered Clinical Cancer Research: A Workshop

September 29-30,2025

National Cancer Policy Forum
Forum on Drug Discovery, Development, and Translation

Workshop Website

Keck Center Room 100
500 Fifth Street, NW
Washington, DC 20001

MONDAY, SEPTEMBER 29, 2025 EASTERN TIME ZONE	
8:00 am	**Registration** (30 minutes)
8:30 am	**Welcome and Introductory Remarks** (10 minutes) Gwen Darien *(Participating Virtually)* and Lawrence Shulman, Planning Committee Co-Chairs
8:40 am	**Keynote: The Current State of the Science of Person-Centered Clinical Research** (~25 minutes) • Monica Bertagnolli, Harvard Kennedy School of Government *(Participating Virtually)*
9:05 am	**Session 1: Roundtable Discussion: Integrating Person-Centeredness into Clinical Cancer Research** (~1 hour, 35 minutes) *Co-Moderators:* *Gwen Darien, Patient Advocate Foundation (Participating Virtually)* *Randy Jones, University of Virginia* *Session Objective:* Discuss the challenges and opportunities of person-centered clinical research, including pharmacological and non-pharmacological clinical trials and population-based research across the cancer care continuum, from the perspectives of patients and caregivers. **Panelists** • Ricki Fairley, Touch: The Black Breast Cancer Alliance (BBCA) (~7 minutes) • Julia Maués, Guiding Researchers and Advocates to Scientific Partnerships (GRASP) (~7 minutes) • Ji Im, CommonSpirit Health (~7 minutes) • Susan Mazanec, Case Western Reserve (~7 minutes) **Panel Discussion and Audience Q&A** (~60 minutes)
10:40 am	**Break** (15 minutes)
10:55 am	**Session 2: Designing and Operationalizing Person-Centered Clinical Cancer Research** (~1 hour, 35 minutes) *Co-Moderators:* *Lawrence Shulman, University of Pennsylvania* *Gail Eckhardt, Baylor College of Medicine*

	Session Objective: Examine the challenges and opportunities of person-centered clinical research, broadly defined to include pharmacological and non-pharmacological clinical trials and population-based research across the cancer care continuum, from the perspective of researchers. **Patient-Reported Outcomes for Evaluating Toxicities (Adverse Events) in Cancer Clinical Research** (~10 minutes) • Ethan Basch, University of North Carolina at Chapel Hill **Assessing Symptoms and Functioning in Clinical Cancer Research to Evaluate Treatment Benefit** (~10 minutes) • Bryce Reeve, Duke University School of Medicine **Hybrid Decentralization Model for Early Phase Clinical Cancer Research** (~10 minutes) • Pat LoRusso, Yale University *(Participating Virtually)* **Facilitating Clinical Trials in Under-Resourced and Rural Areas** (~10 minutes) • Ruma Bhagat, Genentech **Engaging the Community in Clinical Cancer Research** (~10 minutes) • Howard "Skip" Burris, Sarah Cannon Research Institute **Panel Discussion and Audience Q&A** (~45 minutes)
12:30 pm	**Break** (1 hour)
1:30 pm	**Session 3: Building the Evidence Base for Person-Centered Clinical Cancer Research** (~1 hour, 35 minutes) *Co-Moderators:* *Roy Herbst, Yale University* *Robert Winn, Massey Comprehensive Cancer Center, Virginia Commonwealth University* *Session Objective:* Discuss lessons learned to inform and guide the next steps for robust evidence generation to improve person-centered clinical research and make clinical trials more efficient. **Overview: Person-Centered Standard and Pragmatic Clinical Trial Designs** (~10 minutes) • Roy Herbst, Yale School of Medicine **Learnings from PCORI's Foundational Expectations for Partnerships in Research** (~10 minutes) • Kristin Carman, Patient-Centered Outcomes Research Institute (PCORI) **Recruitment and Retention of Diverse Populations in Clinical Cancer Research** (~10 minutes) • Chanita Hughes-Halbert, University of Southern California **Insights from the European Organisation for Research and Treatment of Cancer** (~10 minutes) • Claire Piccinin, European Organisation for Research and Treatment of Cancer *(Participating Virtually)* **Panel Discussion and Audience Q&A** (~45 minutes)
3:05 pm	**Break** (15 minutes)

3:20 pm	**Session 4: Regulatory and Structural Considerations in the Design of Clinical Cancer Research** (~1 hour, 40 minutes) *Co-Moderators:* *Richard Schilsky, University of Chicago* *Cleo Ryals, Flatiron Health* *Session Objective:* Discuss the regulatory and structural considerations related to the design of clinical cancer research. **Engaging the National Clinical Trials Network Clinical Trial Groups** (~20 minutes) • Richard Schilsky, University of Chicago • Deborah Collyar, Patient Advocates In Research **Aligning the Goals of Industry and Publicly Funded Clinical Cancer Research With the Goals of Patients** (~10 minutes) • Lawrence Shulman, University of Pennsylvania **Person-Centeredness in Early Phase Clinical Cancer Research** (~10 minutes) • Shivaani Kummar, Oregon Health and Science University **A Pharmaceutical Industry Perspective** (~10 minutes) • Arun Balakumaran, Pfizer Inc. **Regulatory Use of Patient-Reported Outcomes in Oncology** (~10 minutes) • Vishal Bhatnagar, U.S Food and Drug Administration **Panel Discussion and Audience Q&A** (~40 minutes)
5:00 pm	**Adjourn and Reception**

TUESDAY, SEPTEMBER 30, 2025 EASTERN TIME ZONE	
8:00 am	**Registration** (30 minutes)
8:30 am	**Day 2 Welcome** (5 minutes) Lawrence Shulman, Planning Committee Co-Chair
8:35 am	**Session 5: Reporting Findings from Clinical Cancer Research Back to Participants** (~1 hour, 40 minutes) *Co-Moderators:* *Shivaani Kummar, Oregon Health and Science University* *Larissa Nekhlyudov, Brigham & Women's Hospital, Dana-Farber Cancer Institute; Harvard Medical School* *Session Objective:* Examine opportunities and challenges for reporting the findings from clinical cancer research and examine different methodologies for return of results to participants. **Patient Advocacy and Engagement Perspective** (~10 minutes) • Sarah Greene, Cancer Research Advocate **Clinical Bioethics Perspective** (~10 minutes) • Gregory Abel, Dana-Farber Cancer Institute; Harvard Medical School **Research Perspective** (~10 minutes)

	• Jeff Yorio, Texas Oncology *(Participating Virtually)* **A Pharmaceutical Industry Perspective** (~10 minutes) • Edgar Braendle, AVEO Oncology **Reporting Findings in NCI Prevention and Screening Clinical Trials** (~10 minutes) • Lori Minasian, National Cancer Institute **Panel Discussion and Audience Q&A** (~50 minutes)
10:15 am	**Break** (15 minutes)
10:30 am	**Session 6: Summary Discussion with Co-Moderators: Advancing Progress in Person-Centered Clinical Cancer Research** (~1 hour) *Co-Moderators:* *Gwen Darien, Patient Advocate Foundation (Participating Virtually)* *Lawrence Shulman, University of Pennsylvania* Session co-moderators reconvene to summarize key observations and opportunities Session 1: Gwen Darien and Randy Jones Session 2: Lawrence Shulman and Gail Eckhardt Session 3: Roy Herbst and Rob Winn Session 4: Richard Schilsky and Cleo Ryals Session 5: Shivaani Kummar and Larissa Nekhlyudov
11:30 am	**Adjourn**

You may also scan the QR code below to submit questions and comments.
Please state your name and affiliation prior to asking a question.

NATIONAL CANCER POLICY FORUM

Sponsors of the National Cancer Policy Forum

Centers for Disease Control and Prevention

National Institutes of Health/National Cancer Institute

American Association for Cancer Research

American Cancer Society

American College of Radiology

American Society of Clinical Oncology

Association of American Cancer Institutes

Association of Cancer Care Centers

AVEO Oncology

Cancer Center at Illinois

Lilly

Flatiron Health

Merck

National Comprehensive Cancer Network

Novartis Oncology

Oncology Nursing Society

Partners In Health

Patient Advocate Foundation

Pfizer Inc

We are grateful for the support of our sponsors, which is crucial to the work of the Forum.

Innovative Person-Centered Clinical Cancer Research: A Workshop

Planning Committee Roster

Lawrence N. Shulman, MD, MACP, FASCO *(Co-Chair)*
Professor of Medicine
Associate Director
Special Projects
Director
Center for Global Cancer Medicine
Penn Center for Cancer Care Innovation
Abramson Cancer Center
University of Pennsylvania

Gwen Darien, BA *(Co-Chair)*
Executive Vice President
Patient Advocacy and Engagement
Patient Advocate Foundation

Gideon Blumenthal, MD
Vice President
Regulatory Affairs - Oncology
Merck

S. Gail Eckhardt, MD, FASCO
Associate Dean of Experimental Therapeutics
Baylor College of Medicine
Associate Director of Translational Research
Dan L. Duncan Comprehensive Cancer Center

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Chief of Medical Oncology and Hematology
Deputy Director
Yale Cancer Center and Smilow Cancer Hospital
Assistant Dean for Translational Research
Yale School of Medicine

Randy A. Jones, PhD, RN, FAAN
Professor
Associate Dean for Partner Development and Engagement
University of Virginia School of Nursing
Assistant Director
Community Outreach and Engagement
Emily Couric Clinical Cancer Center
University of Virginia

Shivaani Kummar, MD, FACP
Margaret and Lester DeArmond Chair of Molecular Oncology
Division Chief of Hematology and Medical Oncology
Co-Director, Center of Experimental Therapeutics
Associate Chief Executive Officer
Knight Cancer Institute
Oregon Health Science University

Larissa Nekhlyudov, MD, MPH, FASCO
Professor of Medicine
Harvard Medical School
Brigham and Women's Hospital
Clinical Director
Internal Medicine for Cancer Survivors
Dana-Farber Cancer Institute

Megan O'Meara, MD
Head
Oncology Early Stage Development
Pfizer

Cleo A. Ryals, PhD
Senior Director
Research Sciences
Head of Health Equity Research
Flatiron Health

Richard L. Schilsky, MD, FACP, FSCT, FASCO
Professor Emeritus
University of Chicago

Ann Taylor, MD
Former Chief Medical Officer
Board Member
AstraZeneca
Comanche Biopharma

Robert A. Winn, MD
Director
Massey Comprehensive Cancer Center
Senior Associate Dean for Cancer Innovation
Professor of Pulmonary Disease and Critical Care Medicine
Lipman Chair in Oncology
Virginia Commonwealth University School of Medicine
President
Association of American Cancer Institutes

NATIONAL CANCER POLICY FORUM

Innovative Person-Centered Clinical Cancer Research: A Workshop
September 29 - 30, 2025

Speaker Roster

Gregory A. Abel, MD, MPH
Professor of Medicine
Dana-Farber Cancer Institute

Arun Balakumaran, MD, PhD
Heme Oncology Therapeutic Area Head
Pfizer

Ethan Basch, MD, MSc
Physician-in-Chief
Chief of Oncology
University of North Carolina at Chapel Hill

Monica Bertagnolli, MD
Senior Fellow - Healthcare Policy
Harvard Kennedy School of Government

Ruma Bhagat MD, MPH
Senior Director
Health Equity & Population Science (HE&PS)
Product Development
Genentech, Inc. (A Member of the Roche Group)

Vishal Bhatnagar, MD
Associate Director for Patient Outcomes
Oncology Center of Excellence
U.S. Food and Drug Administration

Edgar Erwin Braendle, MD, PhD
Chief Medical Officer
AVEO Oncology, an LG Chem company

Howard A. Burris, III, MD, FACP, FASCO
President
Chief Medical Officer
Sarah Cannon Research Institute (SCRI)

Kristin L. Carman, PhD, MA
Director
Public and Patient Engagement
Patient-Centered Outcomes Research Institute (PCORI)

Deborah Collyar
President
Patient Advocates In Research (PAIR)
Co-Director
The INSTITUTE@One Cancer Place

Ricki Fairley
Chief Executive Officer
Co-Founder
TOUCH, The Black Breast Cancer Alliance

Sarah Greene, MPH
Executive Director
Cancer Research Advocate

Chanita Hughes-Halbert, PhD
Vice Chair for Research and Professor
Department of Population and Public Health Sciences
Dr. Arthur and Priscilla Ulene Chair in Women's Cancer
Keck School of Medicine
Associate Director for Cancer Equity
Norris Comprehensive Cancer Center
University of Southern California

Ji Im, MPH
Community Health Strategist and Advocate
System Senior Director
Community and Population Health
CommonSpirit Health

Patricia Mucci LoRusso, DO, PhD
Director
Early Phase Clinical Trials Program
Associate Center Director
Experimental Therapeutics
Yale Cancer Center, Yale University
Immediate Past President
American Association for Cancer Research (AACR)

Julia Maués, MA
Co-Founder
Guiding Researchers and Advocates to Scientific Partnerships (GRASP)
Patient-Centered Dosing Initiative (PCDI)

Susan R. Mazanec, PhD, RN, AOCN, FAAN
Associate Professor
PhD Program Director
The Arline H. and Curtis F. Garvin Professor in Nursing Excellence
Frances Payne Bolton School of Nursing
Case Western Reserve University
University Hospitals Seidman Cancer Center

Lori Minasian, MD, FACP
Deputy Director
Division of Cancer Prevention
National Cancer Institute
National Institutes of Health

Claire Piccinin, MSc
Researcher
Quality of Life Department
European Organisation for Research and Treatment of Cancer

Bryce B. Reeve, PhD
Professor of Population Health Sciences
Professor of Pediatrics
Director of the Center for Health Measurement
Duke University School of Medicine

Jeff Yorio, MD
Hematologist-Oncologist
Central Texas Site Research Leader
Chief of Hematology-Oncology
Texas Oncology-Austin Central
Sarah Cannon Research Institute at Texas Oncology
Ascension Seton Medical Center Austin

Innovative Person-Centered Clinical Cancer Research: A Workshop
September 29 - 30, 2025

Planning Committee Biosketches

Gwen Darien, BA (*Co-Chair*)
Patient Advocate Foundation

Gwen Darien is a longtime patient advocate who has played leadership roles in some of the country's preeminent nonprofit organizations. As executive vice president for patient advocacy, engagement and education, Gwen leads programs that link Patient Advocate Foundation's direct patient service programs to PAF patient education and system change initiatives, with the goal of improving access to equitable, affordable, quality health care.
As a four-time cancer survivor herself, Darien came into cancer advocacy expressly to change the experiences and outcomes for the patients who came after her, to change the public dialogue about cancer and other life-threatening illnesses. The foundational value for her advocacy work is achieving equitable health outcomes for everyone. As editor and publisher of Mamm, a magazine for women with breast or reproductive cancer, she published features on previously taboo subjects, such as dating after a mastectomy, along with the more expected academic features on news and policy analysis.

With these goals in mind, in 2005 she started the first stand-alone advocacy entity in a professional cancer research organization at the American Association for Cancer Research. At AACR, she launched CR magazine – a magazine for people with cancer and those who care for them. Later, she served as the executive vice president of programs and services at the Cancer Support Community. In each role, Darien championed placing patients at the center of health system change, whether it is for research, public policy or direct services.

Gwen serves on a wide range of program committees and workshop faculties. Gwen is a member of the National Cancer Policy Forum of the National Academies of Science, Engineering and Medicine for which she is co-chairing the forthcoming workshop, Innovative Person-Centered Cancer Research. Gwen co-chairs the Individual and Community Health Goals working group of the National Academy of Medicine's Commission on Investment Imperatives for a Healthy Nation. She is the past Chair of PCORI's Patient Engagement Advisory Panel.
and was founding Chair of Community Engagement in Genomics Working Group of the National Human Genome Research. Gwen also writes about her experiences as an advocate and cancer survivor. Her piece, Transformation: My Experience as a Patient and an Advocate in Three Chapters appeared in the National Academy of Medicine Perspectives.

Darien is a graduate of Sarah Lawrence College, where she also served as an adviser for their Health Advocacy program.

Lawrence N. Shulman, MD, MACP, FASCO (*Co-Chair*)
University of Pennsylvania

Dr. Lawrence N. Shulman is Professor of Medicine at the Perelman School of Medicine, the Associate Director for Special Projects at the Abramson Cancer Center at the University of Pennsylvania, and Co-Director of the Center for Global Oncology. He received his MD from Harvard Medical School and trained in Hematology and Oncology at the Beth Israel Hospital in Boston, MA.

Dr. Shulman is the Past-Chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academy. He is the former Chair of the American Society of Clinical Oncology Quality of Care Committee and the Commission on Cancer's Quality Integration Committee. A specialist in the treatment of patients with breast cancer, his research includes development of new cancer therapies, and implementation of cancer treatment programs in low-resource settings.

In this regard, Dr. Shulman serves as Senior Oncology Advisor to the non-profit organization Partners In Health (PIH). The PIH mission includes the establishment of national cancer treatment programs with the Ministries of Health in Rwanda, Lesotho, and Haiti, programs for which he plays a seminal leadership role.

Gideon Blumenthal, MD
Merck

Dr. Gideon Blumenthal is a Medical Oncologist who is currently serving as Vice President, Global Clinical Development and Section Head of the Asset Development Group for Oncology at Merck & Co. In this role, he oversees the Asset Leads for MK-2870 (Sac-TMT) a novel TROP2 ADC, MK-1084 a next-generation KRAS G12C inhibitor and MK-1022, a novel HER3 ADC. The asset teams are charged with overseeing end-to-end clinical development and multi-functional strategy across cancers and across the product lifecycle, from dose-finding and proof of concept to Phase 3 registrational clinical trials. Prior to this role in Clinical Development, Gideon served as Oncology Regulatory Affairs Therapeutic Area Head at Merck, overseeing Genitourinary, Gastrointestinal, Head and Neck Cancer, and Hematologic Malignancies, leading regulatory strategy for Pembrolizumab as well as other assets including Belzutifan, Olaparib, and Lenvatinib.

Prior to joining Merck in 2020, Dr Blumenthal spent over a decade at the US Food and Drug Administration in Oncology. He initially served as a Medical Officer, then Clinical Team Leader, followed by Deputy Director in the Office of Hematology Oncology Products, and most recently as a founding Deputy Center Director of the Oncology Center for Excellence. While at FDA, he oversaw the development programs leading to groundbreaking approvals of novel targeted and immunotherapy treatments for patients with cancer. Dr Blumenthal trained in internal medicine at the University of Maryland School of Medicine, followed by a hematology/ oncology fellowship at the National Cancer Institute. He was an attending physician in the NCI Thoracic Oncology clinic during his time at FDA. He received numerous awards, including the 2018 American Society for Clinical Oncology Public Service Award. He has co-authored over 100 articles in the Oncology and Drug Development peer-reviewed literature and has authored numerous book chapters.

S. Gail Eckhardt, MD
Baylor College of Medicine

Dr. S. Gail Eckhardt is a tenured Professor, Associate Dean of Experimental Therapeutics, and holds the Albert and Margaret Alkek Foundation Chair at Baylor College of Medicine. She is also the Associate Director of Translational Research at the Dan L Duncan Comprehensive Cancer Center. Dr. Eckhardt has served on numerous committees and study sections, including the ASCO Molecular Oncology Task Force, the ASCO Board of Directors, the FDA Oncology Drugs Advisory Committee, and the National Cancer Institute (NCI) Cancer Centers Study Section. She serves on 10 external advisory boards of NCI-designated cancer centers, was a lead mentor in ASCO's Leadership Development Program, past member of the Board of Directors of the Association of American Cancer Institutes (AACI) and previous Chair of the Cancer Prevention and Research Institute of Texas' Clinical Trials Advisory Committee. She is a current member of the National Academies of Science, Engineering, and Medicine's Cancer Policy Forum, ASCO's TAPUR Study Scientific Advisory Group, the Scientific Advisory Committee of SU2C, and the NCI's NCAB Working Group on Extramural Research Concepts and Programs. Dr. Eckhardt was awarded ASCO's Women Who Conquer Cancer Mentorship Award in 2022. She serves on the Board of Directors of Exelixis and the Scientific Advisory Board of Amgen.

Dr. Eckhardt has been Principal Investigator on grants involving early clinical trials and colorectal cancer research, has conducted numerous early phase clinical trials and has published over 250 manuscripts. Her area of interest is in the preclinical and early clinical development of combinations of molecularly targeted compounds, with a disease focus on colorectal cancer. Dr. Eckhardt earned her undergraduate degree in chemistry from Stephen F. Austin State University and her medical degree from the University of Texas Medical Branch in Galveston. She completed her internship and residency in Internal Medicine at the University of Virginia Medical School, followed by a post-doctoral research

fellowship in Experimental and Molecular Medicine at Scripps Research Institute in La Jolla, California, and a fellowship in Medical Oncology at the University of California San Diego.

Roy S. Herbst, MD, PhD
Yale University

Dr. Roy S. Herbst is Ensign Professor of Medicine at Yale School of Medicine, Deputy Director for Yale Cancer Center (YCC), Chief of Medical Oncology and Hematology, and Program Director, Master of Health Science—Clinical Investigation track at Yale School of Medicine. He is the principal investigator (PI) of the Yale SPORE in Lung Cancer, PI of the YCC Advanced Training Program for Physician-Scientists, PI on the National Cancer Institute (NCI) NCTN LAPS Grant, and PI of the Yale-AstraZeneca Alliance, which has 12 projects spanning various cancer types.

Dr. Herbst has led Phase I development of multiple targeted agents for non-small cell lung cancer, including gefitinib, cetuximab, bevacizumab, axitinib, atezolizumab, and anti-PD1/PDL1 therapies. Additionally, he has helped bring targeted therapy to early-stage disease as the PI of the adjuvant osimertinib study (ADAURA). He co-led MD Anderson's BATTLE-1 effort, which led to the BATTLE-2 trial defining biomarkers as standard for the use of targeted therapies. He served as the national PI of the SWOG S0819 trial and held the role of founding PI for the NCI Lung Cancer Master Protocol (Lung-MAP, S1400) for a decade. He has authored or coauthored more than 450 publications, and his work published in Nature was awarded Clinical Research Forum's 2015 Herbert Pardes Clinical Research Excellence Award.

Dr. Herbst is a member of the National Cancer Policy Forum for which he organized National Academy of Medicine meetings focused on policy issues in personalized medicine, tobacco control, and public-private partnerships. He is an elected member of the NCI Thoracic Malignancies Steering Committee and the chair of the American Association for Cancer Research Science Policy and Government Affairs Committee. He is a member of the Association of American Physicians.

Dr. Herbst received the 2022 Giants of Cancer Care® award for lung cancer and was selected by the Friends of Cancer Research as one of their 25 scientific and advocacy leaders who have been instrumental over the last 25 years in making significant advancements for patients. Most recently, Dr. Herbst received the 2024 Ezra Greenspan Award from the Chemotherapy+ Foundation for the work he has done throughout his career and the work he continues to do for lung cancer patients.

Randy A. Jones, PhD, RN, FAAN
University of Virginia

Dr. Randy Jones is Professor and the Associate Dean for Partner Development and Engagement at UVA's School of Nursing, as well as the Faculty Assistant Director of the Community Outreach and Engagement Core at UVA's Comprehensive Cancer Center. His research focuses on health disparities, decision making, cognitive impairment, palliative care and leveraging technology to improve cancer care and other chronic diseases. He has received funded research grants from organizations such as the National Institutes of Health (NIH), Robert Wood Johnson Foundation, American Cancer Society, and the American Nurses Foundation.

In particular, Dr. Jones has been active in the community providing education, recruiting, and informing the public about clinical trials and different diseases that affect vulnerable populations. Dr. Jones is also a member of the iTHRIV Clinical Research Access Committee, which helps spread information on clinical research throughout the local community, especially for minority groups and rural populations.



Shivaani Kummar, MD, FACP
Oregon Health and Science University

Dr. Shivaani Kummar is Associate CEO, Knight Cancer Institute, Margaret and Lester DeArmond Chair of Molecular Oncology, Division Chief of Hematology and Medical Oncology, co-Director of the Center of Experimental Therapeutics, Oregon Health & Science University (OHSU), Portland, Oregon, USA. She specializes in conducting pharmacokinetic and pharmacodynamic driven first-in-human trials tailored to make early, informed decisions regarding the suitability of novel molecular agents for further clinical investigation. She is a member of scientific planning committees of national and international professional organizations and has authored over 180 peer reviewed publications, 9 book chapters, and co-edited a book on 'Novel Designs of Early Phase Trials for Cancer Therapies'. She is also the PI for an NCI T32 grant to train MDs and PhDs in anticancer drug development.

Larissa Nekhlyudov, MD, MPH
Brigham and Women's Hospital; Harvard Medical School; Dana-Farber Cancer Institute

Dr. Larissa Nekhlyudov is Professor of Medicine at Harvard Medical School and is a practicing primary care physician at the Brigham & Women's Hospital in Boston, Massachusetts. She is also Clinical Director, Internal Medicine for Cancer Survivors at the Dana-Farber Cancer Institute where she offers clinical care for long term survivors of childhood and adult cancers. Dr. Nekhlyudov is particularly interested in improving the care of cancer survivors and the interplay between primary and oncology care. Her publications (including journal articles, book chapters and two books) as well as her broad-ranging educational programs have promoted global awareness among health care providers about the ongoing needs of cancer patients across the care continuum.

Dr. Nekhlyudov has been at the forefront of the field of cancer survivorship, nationally and internationally, by leading and participating in the development of policies, clinical guidelines, educational programs, and research. She is Deputy Editor of the Journal of Cancer Survivorship and Associate Editor at the Journal of the National Cancer Institute. In addition to serving on the Executive Board of the Cancer and Primary Care Research International Network (Ca-PRI), Dr. Nekhlyudov is an active member of the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), the Multinational Association for Supportive Care in Cancer (MASCC), the National Academies of Sciences, Engineering and Medicine (NASEM) National Cancer Policy Forum, among others. She was a Visiting Scholar at the National Cancer Institute where she developed a framework for quality cancer survivorship care. Throughout her career, Dr. Nekhlyudov has been dedicated to teaching and mentoring students, residents, fellows, and faculty. She has also been committed to empowering cancer survivors and caregivers through educational programs and advocacy, offering volunteer support to organizations including the National Coalition for Cancer Survivorship, Leukemia & Lymphoma Society, Hodgkins International and Survivor Journeys, among others.

Megan O'Meara, MD
Pfizer

Dr. Megan O'Meara assumed the role of Head of Oncology Early Stage Development at Pfizer following its acquisition of Seagen in 2023. In this capacity, she oversees the clinical development of the early-stage portfolio, including strategy and execution for oncology trials. During her more than 12-year career at Seagen, Dr. O'Meara progressed through roles of increasing responsibility, ultimately leading both early and late-stage clinical development and managing the immuno-oncology development strategy.
A longstanding member of the American Society of Clinical Oncology and the American Association for Cancer Research, as well as a 2024 Working For Cures Champion, Dr. O'Meara is dedicated to advancing science and medical innovation to enhance outcomes for cancer patients.

Dr. O'Meara is a board-certified Medical Oncologist who earned her M.D. from the University of Arizona. She completed her Internal Medicine training at the University of Washington, followed by an oncology fellowship at the Fred Hutchinson Cancer Research Center/University of Washington and a post-doctoral translational research fellowship with the Cancer Vaccine Institute at UW Medicine.

Cleo A. Ryals, PhD
Flatiron Health

Dr. Cleo A. Ryals is the Head of Health Equity Research at Flatiron Health, where she is tasked with developing and executing Flatiron's company-wide health equity strategy with the goal of advancing cancer health equity through real-world evidence generation. Dr. Ryals is a health services researcher by training with expertise in cancer health equity, real-world data and evidence generation, health equity research methodology and data analytics, clinical trial diversity, and community engagement. She is a nationally recognized and highly sought after health equity researcher and leader with several publications on topics related to health equity and oncology care. Prior to joining Flatiron Health, Dr. Ryals was a tenured Associate Professor of Health Policy and Management at the UNC Chapel Gillings School of Global Public Health, where she built substantial health equity research and training programs and was the Founding Director of the Centering Racial Equity in Data Science (CREDS) Initiative at the UNC Lineberger Comprehensive Cancer Center. Dr. Ryals has also held positions within multiple federal offices/agencies, including the former United States Senate Office of Barack Obama, the Office of the National Coordinator for Health Information Technology, and the Government Accountability Office. In 2019, Dr. Ryals was recognized as a '40 Under 40' Leader in Minority Health by the National Minority Quality Forum and Congressional Black Caucus. Dr. Ryals holds a PhD in Health Policy from Harvard University.

Richard L. Schilsky, MD, FACP, FSCT, FASCO
Professor Emeritus, University of Chicago

Dr. Richard L. Schilsky is a renowned oncologist and clinical trialist with a career spanning over four decades. He is recognized for his expertise in gastrointestinal cancers, cancer pharmacology, and precision medicine. Dr. Schilsky served as President of the American Society of Clinical Oncology (ASCO) from 2008-2009 and as Chief Medical Officer and Executive Vice President of ASCO from 2013 to 2021. Prior to that, he spent nearly 30 years at the University of Chicago, where he held many leadership roles, including Director of the Comprehensive Cancer Center, Associate Dean for Clinical Research and Chief of Hematology/Oncology.

From 1995 to 2010, Dr. Schilsky served as chair of the Cancer and Leukemia Group B, a national cooperative cancer research group funded by the National Cancer Institute (NCI), now part of the Alliance for Clinical Trials in Oncology. He has extensive experience working with both the NCI and the Food and Drug Administration (FDA) having served as a member and chair of the NCI Board of Scientific Advisors, as a member of the NCI Clinical and Translational Research Committee, and as a member and chair of the Oncologic Drugs Advisory Committee of the FDA. He is a former member of the National Cancer Policy Forum and presently serves as chair of the Board of the Reagan-Udall Foundation for the FDA, and as a member of the Board of Directors of Friends of Cancer Research. Dr. Schilsky has served on the editorial boards of many cancer journals, including the Journal of Clinical Oncology. He presently serves on the editorial board of the New England Journal of Medicine. Dr. Schilsky is the author of more than 450 original research articles, reviews and commentaries.

Ann Taylor, MD
Formerly at AstraZeneca

Dr. Ann Taylor is now retired from full time work after last serving as Chief Medical Officer at AstraZeneca. She is now serving on the Boards of Unlearn.AI, Comanche BioPharma, and the TBAlliance, as well as serving on the Scientific Advisory Board of Crinetics Pharmaceuticalslic, the New England Advisory Board of The Trust for Public Land and on the NASEM Forum on Drug Development, Discovery, and Translation as Co-Chair. She got her BA from the University of California San Diego, her M.D. from Harvard Medical School, and completed her residency in Internal Medicine and a fellowship in Endocrinology and Metabolism at Massachusetts General Hospital before joining the faculty there. Her academic career focused on the pathophysiology of female reproductive disorders, especially Polycystic Ovary Syndrome. In 2001 she joined the pharmaceutical industry with roles of increasing responsibility at Pfizer, Novartis, and Medimmune before becoming Chief Medical Officer.

Robert A. Winn, MD
Massey Comprehensive Cancer Center, Virginia Commonwealth University

Dr. Robert A. Winn is the Director of Virginia Commonwealth University Massey Comprehensive Cancer Center. His current basic science research focuses on the translational aspects of the role that proliferation pathways and cellular senescence play in lung cancer. Winn has also brought the importance of the concept of ZNA (i.e., one's zip code or neighborhood of association) and its impact on DNA and biological outcomes to the forefront in basic and translational research. He is a principal investigator on several community-oriented projects funded by the NIH and National Cancer Institute. Winn is the President of the Association of American Cancer Institutes (AACI); Chair of the National Cancer Policy Forum of the National Academies of Sciences, Engineering, and Medicine; and a member of the Board of Directors for the American Cancer Society and LUNGevity Foundation. Winn holds a BA from the University of Notre Dame and an MD from the University of Michigan Medical School in Ann Arbor. He completed an internship and residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago and a fellowship in pulmonary and critical care medicine at the University of Colorado Health Sciences Center in Denver.

Speaker Biosketches



Gregory A. Abel, MD, MPH
Dana-Farber Cancer Institute

Dr. Abel is an outcomes researcher and hematologic oncologist at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, where he is also a member of the Center for Bioethics. He helps run DFCI's Older Adult Hematologic Malignancy (OHM) geriatric hematology research program, serves as Co-Chair of the DFCI Ethics Advisory Committee, is Director of Clinical Research for the Division of Population Sciences, and leads DFCI's Clinical Ethics Service. His research lab applies health services research methods to understand the experiences of patients with blood cancers and develop interventions to improve their care.

Dr. Abel is also interested in evaluating how cancer and its therapies affect outcomes such as function and quality of life. Through his work and collaboration with researchers in oncology, hematology, geriatrics, bioethics, and energy balance, he aims to ameliorate the impact of cancer and its treatment from diagnosis to the end of life.

Arun Balakumaran MD, PhD
Pfizer

Dr. Arun Balakumaran serves as the Heme Oncology Therapeutic Area Head at Pfizer, where he leads strategic development and execution across a portfolio of innovative therapies in hematologic malignancies. With a background spanning academic medicine, translational research, and industry leadership, Dr. Balakumaran brings a unique perspective to oncology drug development.

Prior to joining Pfizer, he held Chief Medical Officer roles in biotech companies, where he oversaw clinical strategy and advanced novel therapies from early development through pivotal trials. He is a key contributor to Pfizer's oncology strategy, driving initiatives that aim to improve patient outcomes and expand access to cutting-edge treatments.

Ethan Basch, MD, MSc
University of North Carolina at Chapel Hill

Dr. Ethan Basch is Physician-in-Chief of the North Carolina Cancer Hospital and Chief of Oncology at the University of North Carolina, where he is a Distinguished Professor of Medicine and of Public Health. He has conducted research on patient-reported outcomes for more than 20 years.

His research group established that up to half of patients' symptoms go undetected during cancer care, and that symptom monitoring with patient-reported outcomes closes that gap and improves clinical outcomes. He has served on the Board of Directors of ASCO, the Board of Scientific Advisors of the NCI, the Methodology Committee of PCORI, and as an Associate Editor at *JAMA*.

Monica M. Bertagnolli, MD
Harvard Kennedy School of Government

Dr. Monica M. Bertagnolli is a surgical oncologist and cancer researcher currently serving as a Fellow in Healthcare Policy at the Harvard Kennedy School. From November 2023- January 2025 she was the 17th director of the National Institutes of Health. Prior to this, she was the Director of the National Cancer Institute (NCI), Richard E. Wilson Professor of Surgery at Harvard Medical School, and Chief of Surgical Oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute. Throughout her career, Dr. Bertagnolli has been at the forefront of the field of clinical oncology. Her laboratory focused on understanding the genetic drivers of gastrointestinal cancer and the role of inflammation in cancer growth. She led translational science initiatives within the NCI-funded National Clinical Trials Network (NCTN), and served as Chair of the Alliance for Clinical Trials in Oncology, a NCTN member organization. Over the past decade, Dr. Bertagnolli has championed collaborative initiatives to enable a learning healthcare system by transforming the data infrastructure for clinical research. She is a past president of the American Society of Clinical Oncology and served on the board of directors of the American Cancer Society and the Prevent Cancer Foundation. Dr. Bertagnolli was elected to the National Academy of Medicine in 2021. She graduated from Princeton University with a Bachelor of Science in Engineering degree and attended medical school at the University of Utah. She trained in surgery at Brigham and Women's Hospital and was a research fellow in tumor immunology at the Dana-Farber Cancer Institute.

Ruma Bhagat MD, MPH
Genentech, Inc.

Dr. Ruma Bhagat is a physician by training and holds a Master in Public Health degree with a focus on International Health Systems from Tulane University. With over 20 years of experience in the pharmaceutical industry, she is a seasoned clinical research professional and currently serves as Senior Director in the Global Health Equity and Population Science team.

Throughout her career, Dr. Bhagat has held increasingly complex roles in Clinical Science, Clinical Operations, and Process Excellence, building a strong foundation in the drug development lifecycle. She leads cross-functional initiatives aimed at advancing health equity and promoting inclusive research by broadening the scientific representation of historically understudied patient populations in clinical trials.

An intrapreneur at heart, Dr. Bhagat is passionate about driving organizational change and fostering innovation in how research is conducted. She is a recognized thought leader and advocate for inclusivity in clinical research, often emphasizing that “research without inclusiveness is not research.” Her work is rooted in the belief that equitable representation in clinical trials is essential to reducing global healthcare disparities and ensuring timely access to treatments for all patients.

Vishal Bhatnagar, MD
U.S. Food and Drug Administration

Dr. Vishal Bhatnagar is a medical oncologist/hematologist and the Associate Director for Patient Outcomes in the OCE. His interests include patient reported outcomes, patient preference and incorporation of patient experience in oncology trials. In his current role, he leads the OCE’s Patient-Focused Drug Development program. Dr. Bhatnagar has a strong clinical interest in multiple myeloma and previously served in the Division of Hematology Products, where he participated in the approval of numerous myeloma therapies. Dr. Bhatnagar received his BA in Political Science and his medical degree at the George Washington University. He completed his internal medicine residency and hematology/oncology fellowship at the University of Maryland.

Edgar Erwin Braendle, MD, PhD
AVEO Oncology, an LG Chem company

Dr. Edgar Braendle has served as Chief Medical Officer of AVEO Oncology, an LG Chem company since March 2024, overseeing the company's early- and late-stage oncology product development. Prior to joining AVEO Oncology, Dr. Braendle held different senior positions including Chief Development Officer of Autolus Therapeutics Plc, Chief Medical Officer and Global Head of Development at Sumitomo Dainippon Pharma Oncology, President and CEO of ARUP Laboratories and Senior Vice President, and Global Head of Precision Medicine for Novartis AG.

Before joining the life sciences industry, Dr. Braendle was an attending physician and assistant professor of urology at the University of Ulm, Germany. Dr. Braendle's research focused on early and late-stage drug development and translational science with a track record of obtaining worldwide approval for six new chemical entities and different diagnostics.

Dr. Braendle is a member of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH). Dr Braendle is the recipient of multiple industry and academic awards, including the Maximilian Nitze Award from the German Urology Society. Dr. Braendle received his medical degree and his PhD at RWTH Aachen University in Germany, followed by specialty training in medical oncology, urology and pharmacology. Dr. Braendle is also an associate professor at the University of Ulm, Germany.

Howard A. Burris, III, MD, FACP, FASCO
Sarah Cannon Research Institute

Dr. Howard A "Skip" Burris, III serves as President of Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials. In addition to his clinical expertise, Dr. Burris is known for his leadership in business strategy. Most recently, Dr. Burris helped to lead the formation of SCRI's joint venture with US Oncology Research in 2022 to expand access to clinical trials for patients seeking the latest treatment options close to home.

As a well-respected key opinion leader globally, Dr. Burris was elected by his peers to serve as the president of the American Society of Clinical Oncology (ASCO 2019-2020 term and has continued to hold several leadership positions on behalf of the ASCO community. Prior to his term as president, Dr. Burris had served in a variety of leadership roles over many years, including the ASCO Board of Governors, ASCO Audit Committee, and as chair of the ASCO Nominating Committee. Currently, he is chair of the Board for the ASCO Conquer Cancer Foundation.

Dr. Burris received his undergraduate degree at West Point, his medical degree from the University of South Alabama in 1985, and performed his residency and fellowship in hematology/oncology at Brooke Army Medical Center in San Antonio. While there, he served as director of clinical research at the Institute for Drug Development of The Cancer Therapy and Research Center, and was an associate professor at The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.

Kristin L. Carman, PhD
Patient-Centered Outcomes Research Institute

Dr. Kristin L. Carman is the Director of Public and Patient Engagement at the Patient-Centered Outcomes Research Institute (PCORI). In this position, she is responsible for leading and directing PCORI's overall efforts to see that patients and other health care stakeholders are fully involved in and guide all aspects of PCORI's work and developing the science of engagement. In her role, she leads a team that helps ensure that PCORI's unique, patient-centered and stakeholder approach to health care research shapes the research we fund and the culture of research more broadly. She also leads the science of engagement, including the launch of a new PCORI initiative to fund research on engagement. Dr. Carman previously was at the American Institutes for Research, where she served as Vice President and Director of the Center for Patient and Consumer Engagement, and Director of the Health Policy and Research Group, a team of more than 100 health services research professionals. In that role, she helped conduct research on issues of public importance in health care quality, access, and financing; comparative effectiveness; patient and family engagement; health systems improvement; public deliberation; and health-related communications. She led groundbreaking engagement projects funded by the Agency for Healthcare Research and Quality (AHRQ), and numerous foundations including the California HealthCare Foundation, Moore Foundation, and Robert Wood Johnson. Dr. Carman has spearheaded engagement research projects including a randomized clinical trial on deliberative methods, development of an influential framework on engagement in health care, and the development and translation of complex scientific information and concepts for the public and patients. She has published extensively and has worked closely with many health care stakeholders throughout her career. She also previously served as an inaugural member of PCORI's Advisory Panel on Patient Engagement.

Deborah Collyar
Patient Advocates In Research

Deborah Collyar is an internationally recognized cancer survivor and advocate who brings patient realities into health research through the Patient Advocates In Research (PAIR) network. She puts diseases into perspective while sharing valuable patient viewpoints. Deb serves on countless committees and boards, speaks to professional and public groups, writes in plain language, & helps all patients find their voices while applying her business, IT, communication, strategy, policy, implementation, and training skills to bridge gaps between patients, scientists, medical providers, companies, governments, and non-profits.

She also infuses patient representatives, hundreds of whom she has trained, into projects and gathers relevant patient input for programs and policies at grassroots, national and international levels. Key insights are delivered throughout discovery, development, clinical trials, results reporting, data-sharing, standards, genomics, and into clinical practice. Deb's many collaborations include AACR, Association of Community Cancer Centers (ACCC), ARHQ, American Statistical Association (ASA), ASCO, Cancer Precision Medicine Commons (CPMC), Drug Information Association (DIA), Health Literacy Media (HLM), the Institute for Clinical and Economic Review (ICER), US National Academies of Science, Engineering and Medicine (NASEM), NIH, NCI, the Oncology Research Information and Exchange Network (ORIEN), Pharma Preanalytics Working Group (PPWG), the Society for Immunotherapy of Cancer (SITC), and Patient Advocacy Groups to improve clinical results and increase patient engagement.

Recently, Deb also became Co-Director of The INSTITUTE at One Cancer Place which teaches cancer as a foreign language, clarifies the cancer landscape, and builds patient leaders.

Ricki Fairley
TOUCH, The Black Breast Cancer Alliance

As a Triple Negative Breast Cancer Survivor/Thriver, Ricki's personal purpose, passion, mission, ministry, and blessing is to bring focus, attention, research, science, and action to eradicating Black Breast Cancer, and supporting and coaching what she calls her "Blessties" through their breast cancer experience.

Ricki is an award-winning seasoned marketing veteran that has transformed her strategic acumen into breast cancer advocacy. Ricki co-founded and serves as CEO of TOUCH, The Black Breast Cancer Alliance to address Black Breast Cancer as a unique and special disease state, with the overall goal of reducing the mortality rate for Black women. Ricki founded and serves as co-host for "The Doctor Is In," a weekly live breast cancer advocacy web series on the BlackDoctor.org Facebook page that reaches over 3 million viewers. She founded #BlackDataMatters to bring attention to the critical need to advance science for Black breast cancer. In January 2022, she started the When We Tri(al) Movement to change the game on Black women participating in clinical trials to improve outcomes for Black women with breast cancer, sending over 23,000 Black women to a targeted custom user-friendly clinical trial portal. In January 2023, she founded the For The Love of My Gurls Campaign to drive awareness and action effectively reaching and changing perceptions of breast health in over one million young Black women. In 2023, Ricki founded TOUCH Care, the first and only Black woman survivor led 24/7 nurse navigation program supporting breast cancer clinical trials. In 2024, Ricki founded BELONG Launched BELONG (Blesstie Empowering Leadership and Opportunity and Nurturing Growth), to provide education and support for Black-led grass-roots organizations, support groups, and ministries and community leaders. She founded and hosts "SAMBAI Speaks," a monthly web series reaching over 10,000 viewers monthly in the SAMBAI geography of the US, Canada, the UK, Ghana, Nigeria, South Africa, Ethiopia and Kenya. In collaboration with AACR, The Triple Negative Breast Cancer Foundation and Nueva Vida, she launched BlackTNBCSanctuary.org as the only comprehensive resource hub Black and Afro-Latina patients and their families to help navigate a triple negative breast cancer.

Ricki serves on the Board of Trustees for the Triple Negative Breast Cancer Foundation. She is a board member for the Center for Healthcare Innovation, and serves on the American Cancer Society National Breast Cancer Roundtable Steering Committee and the Board of Trustees for Black in Cancer. She is a member of the FNIH Patient Engagement Council, and serves on several patient/advocacy advisory boards. Ricki is a Principal Investigator for the Cancer Grand Challenge Project SAMBAI (Social, Ancestry, Molecular and Biological Analysis of Inequalities) leading a Patient Advocacy team for this global research initiative, led by Dr. Melissa Davis at Morehouse School of Medicine, striving to decode the factors that cause and influence disparate cancer outcomes in unsupported populations of African descent. Ricki has been featured in FiercePharma, Healthline, Oprah Daily, Shondaland, Platform Q Health, Essence Magazine and Salud and Ebony Magazine, The TODAY Show with Hoda and Jenna, Good Morning Washington, to name a few. She is one of 50 of the 800 applicants to receive the Goldman Sachs One Million Black Women Impact Grant funding Black women-led and Black women-serving nonprofits.

Ricki has two daughters, Amanda Brown Lierman and Hayley Brown, 3 granddaughters, Belle, Leia, and Hart, and another grandbaby on the way, who remind her of her purpose every day. Ricki is a graduate of Dartmouth College and holds an MBA from Kellogg Graduate School of Management at Northwestern University.

Sarah M. Greene, MPH
Cancer Research Advocate

Sarah Greene is a consultant, researcher, and cancer survivor with expertise in learning health systems, health communication, electronic health data, and patient-centered care. Much of her career has been focused on building productive, sustainable multi-site networks that conducted applied research on cancer, aging, and communication. She applies a versatile skillset and intellectual curiosity in the areas of digital health, evidence mobilization, and community engagement, and is a recognized national leader in understanding how to bridge research and healthcare delivery using a learning health systems approach. Ms. Greene's perspectives are deeply informed by her recent experience with a cancer diagnosis and successful treatment. Along with a growing portfolio of advocacy work, her recent consulting clients have included the

National Academy of Medicine, Trillium Health Partners, the National Cancer Institute, and Kaiser Permanente. Prior to consulting, she was the inaugural Executive Director of the Health Care Systems Research Network, a national consortium of embedded research centers, where she led all of the organization's activities. Ms. Greene also served as an Associate Director at the Patient-Centered Outcomes Research Institute, providing strategic leadership for PCORI's National Patient-Centered Clinical Research Network, PCORnet®. Throughout her career, Ms. Greene has led numerous strategic planning and change management initiatives and complements these skills with strong technical capabilities including literature synthesis, survey design, evaluation, and qualitative analysis. An accomplished writer and speaker with more than 170 publications and presentations, she has shared her work at the National Academy of Medicine, Society for Gynecologic Oncology, American College of Cardiology, American Medical Informatics Association, and AcademyHealth, among other organizations. Ms. Greene received both her MPH and a BA in Psychology and Italian from Indiana University and resides in Seattle.

Chanita Hughes-Halbert, PhD
University of Southern California

The goal of Dr. Hughes-Halbert's research program is to improve the precision of multilevel strategies for achieving health equity by identifying diverse determinants of minority health and cancer health disparities and by translating this information into sustainable interventions in clinic and community-based settings to improve cancer outcomes and chronic disease management in disparity populations in local and regional geographic areas. Dr. Hughes-Halbert is a nationally recognized expert in cancer prevention and control among diverse populations and her research is supported by numerous grants from the National Cancer Institute, the National Institutes on Minority Health and Health Disparities, and the Veteran's Affairs Medicine Center. Previously, she was a member of the Board of Scientific Advisors at the National Cancer Institute and the National Human Genome Research Institute Advisory Council. Dr. Hughes-Halbert is a past recipient of the AACR Distinguished Lecture in Cancer Health Disparities Award and is a member of the National Academy of Medicine.

Ji Im, MPH
CommonSpirit Health

Ji Im is a system senior director for community and population health at CommonSpirit Health -- a hospital and health system delivering care in 140 hospitals and more than 2,200 care centers serving 24 states. In this role, Ji is responsible for aligning and integrating community health priorities and initiatives to improve health and well-being. Ji leads the strategy and implementation of community-centered care approaches and models with core attributes of community governance, community bank, and contracting between health and community service organizations. Her initiatives focus on fostering cross-sector collaborations, strengthening clinical-community partnerships, and fueling innovation in communities with goals to invest in community infrastructure, capacity, and workforce development. Ji is the co-chair of the individuals and community health goals workstream for the National Academy of Medicine's Commission on Investment Imperatives for a Healthy Nation. Ji is the founding member of the Community Care Hub workgroup for Partnership to Align Social Care, a national learning and action network to build an equitable health and social care ecosystem. Ji serves as a board member for the national nonprofit Pathways Community HUB Institute to promote a sustainable, outcome-based community care coordination and community health worker model led by communities. Ji also serves as a Community Advisory Board member for the Female Asian Never Smokers (FANS) Study led by University of California San Francisco.

Prior to joining CommonSpirit Health, Ji was director of community benefit for Northwell Health in New York. Ji brings program development, strategy, process improvement, and technology integration experiences from Yale-New Haven Hospital, Northwestern Memorial Hospital, George Washington Medical Center, and IT business consulting experience from Accenture. Ji holds a MPH degree in Health Management from Yale and BA in Economics and Philosophy from the College of William & Mary.

Patricia Mucci LoRusso, DO, PhD
Yale Cancer Center, Yale University

Dr. Patricia LoRusso has been a practicing academic medical oncologist performing clinical/translational research in early phase clinical trials for 35 years, spending the first 25 years at Wayne State University/Karmanos Cancer Institute in Detroit, MI and transitioning to Yale University/Yale Cancer Center in 2014. She has had continuous NIH/NCI peer review funding for 33 years, having held a U-grant for early phase clinical trials through the NCI Cancer Therapy Evaluation Program (CTEP) for 28 years. She has also collaborated on numerous other grants and have been an investigator in R01, P01 and P30 funding mechanisms. Understanding the need for team science, she has participated in P50 mechanisms and has been awarded team science grants through such organizations as Stand Up to Cancer (Co-Leader: Melanoma Dream Team), the Department of Defense (DOD) and the Komen Foundation (Co-leader, KG111063:Targeting Stem Cells in Triple-Negative Breast Cancer (TNBC) in Different Racial Populations).

Dr. LoRusso has also been involved in many service disciplines at the NCI and elsewhere. She has reviewed grants for many study sections and has either been an ad hoc (e.g. CCSG, NeXT study sections) or permanent study section member (e.g. Program Project Subcommittee D and Clinical Oncology study sections). She has served on the Investigational Drug Steering Committee (IDSC) since inception (2005-present) and served as its chair from 2011-2013 and 2022-2024. She was a member of the steering committee that convened after the Blue- Ribbon Panel to execute on their recommendations. She served a 9-year term (2015-2024) on the Board of Scientific Council (BSC), reviewing the intramural programs for quality, content, productivity and funding. In addition to serving in NCI positions, Dr. LoRusso has served in leadership positions of several other organizations. She has served on the Board of Directors and numerous scientific and education committees of the American Association for Cancer Research (AACR) as well as the AACR President from 2024-2025. She is currently the Immediate Past President of AACR. She has served on education and scientific committees of the American Society of Clinical Oncology (ASCO), and the steering committee for the Food and Drug Administration (FDA) Accelerating Anticancer Agent Development and Validation Workshop, as examples. Internationally, she has taught several clinical trials educational workshops, educating many physicians and scientists across the globe. She understands how critically important it is to train the next generation of early career investigators to be knowledgeable and proficient in clinical and translational research by providing them leadership opportunities and mentoring. She has worked closely with Cancer Research United Kingdom (CRUK), a UK Welcome Trust which is the second largest funding agency for cancer research. She is currently the chair of their New Agents Committee (NAC), reviewing international proposals relative to drug development of novel agents.

Working closely over the past 3 decades with patients suffering from advanced malignancies, Dr. LoRusso has become an advocate, not only for junior through senior faculty cancer researchers and clinicians, but more importantly for the patients and their caregivers. Having experienced at a young age the death of her own parents from cancer, she understands the urgent need for new cancer discoveries and the potential for longevity and quality of life. She is committed to training the next generation of physician scientists and clinical researchers, to advance novel therapies to increase outreach of novel therapeutics to cancer patients globally.

Julia Maués, MA
Guiding Researchers & Advocates to Scientific Partnerships; Patient-Centered Dosing Initiative

Julia Maués is a patient advocate with over a decade of experience living with metastatic breast cancer. Diagnosed in 2013 while pregnant, Julia has since dedicated herself to amplifying patient voices in cancer research, ensuring that it is inclusive, patient-centered, and reflective of real-world experiences. As the co-founder of GRASP, she bridges the gap between researchers and patients to create more impactful and accessible cancer research. She also leads the Patient-Centered Dosing Initiative (PCDI), advocating for treatment strategies that balance efficacy with patient tolerability, improving overall outcomes.

Julia's advocacy work extends across several organizations, including the San Antonio Breast Cancer Symposium Planning Committee, BIG Against Breast Cancer, and ASCO Guidelines Panels. She has spoken at major conferences such as ASCO, SABCS, ESMO, and FDA meetings, and is a key figure in shaping policies and initiatives that prioritize patient experiences in clinical trials and cancer treatment.

Born in Brazil, Julia is fluent in four languages and has lived in several countries, bringing a global perspective to her work in cancer research and patient advocacy.

Susan R. Mazanec, PhD, RN, AOCN, FAAN
Frances Payne Bolton School of Nursing, Case Western Reserve University
University Hospitals Seidman Cancer Center

Dr. Mazanec is an Associate Professor and the Arline H. and Curtis F. Garvin Professor in Nursing Excellence, at the Frances Payne Bolton School of Nursing at Case Western Reserve University. She is also a Nurse Scientist in the University Hospitals Seidman Cancer Center and a member of the Case Comprehensive Cancer Center, a National Cancer Institute- designated Comprehensive Cancer Center. Dr. Mazanec received her BSN from St. Mary's College, Notre Dame Indiana and her MSN and PhD degrees from Case Western Reserve University.

She has focused her research on patients and their family caregivers undergoing cancer treatment as well as the concept of transitions throughout the trajectory of the cancer experience. She has specifically focused on the transition to post-cancer treatment survivorship, a critical point along the cancer continuum when self-management tasks shift for both patients and caregivers. Dr. Mazanec recently completed an NCI-funded study that tested a psychoeducational intervention, which incorporated structured simulation, or experiential learning, for both technical and communication skills training for family caregivers.

With more than 40 years of oncology clinical nursing experience, Dr. Mazanec is passionate about designing and testing interventions to improve care and advance the science of oncology nursing.

Lori Minasian, MD, FACP
National Cancer Institute

Dr. Lori Minasian, Deputy Director for the Division of Cancer Prevention, is a medical oncologist with extensive experience in NCI clinical trials enterprise. She first led the NCI's Community Clinical Oncology Program (CCOP) for more than 15 years and supported the design, development and conduct of numerous cancer prevention and symptom management clinical trials.

Dr. Minasian has long supported the inclusion of patient reported outcomes in cancer treatment clinical trials. She is one of the senior staff involved in conceptualization and development of the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Event Reporting (PRO-CTCAE). This project emphasizes the importance of incorporating the patient's perception into real-time reporting of adverse events. Dr. Minasian lead the development of Cancer Treatment Tolerability Consortium, whose goal was to stimulate the development of methods to use clinician and patient reported data to better assess and describe patient tolerability to cancer treatment.

Currently, she leads the development of the new Cancer Screening Research Network (CSRN), a new NCI sponsored clinical trials network evaluating different technologies and strategies to improve cancer screening.

Claire Piccinin, MSc
European Organisation for Research and Treatment of Cancer

Claire Piccinin is a researcher in the Quality of Life Department at the European Organisation for Research and Treatment of Cancer (EORTC) where she supports different EORTC Quality of Life Group research projects and initiatives. Currently, her main activities involve overseeing the use of the EORTC Item Library alongside the Item Library Support Team to provide recommendations on the implementation of flexible Item Library-derived measures in patient-reported outcomes (PRO) assessment strategies.

Her research is focused on evaluating trends in EORTC Item Library usage, implementing standardized frameworks to support item/measure selection, and developing guidelines and recommendations to facilitate the use of item libraries for PRO measurement in cancer clinical trials and other research studies, and as part of routine care. She is also actively involved in the International Society for Quality of Life Research (ISOQOL), where she is a member of the Communications Committee and Psychometrics Special Interest Group.



Bryce B. Reeve, PhD
Duke University School of Medicine

Dr. Bryce Reeve is a Professor of Population Health Sciences and Professor of Pediatrics at Duke University School of Medicine. He also serves as Director of the Center for Health Measurement since 2017. Trained in psychometric methods, Dr. Reeve's work focuses on assessing the impact of disease and treatments on the lives of pediatric and adult patients and their caregivers. This includes the development of clinical outcome assessments using both qualitative and quantitative methods, and the integration of patient-centered data in research and healthcare delivery settings to inform decision-making.

From 2000 to 2010, Dr. Reeve served as Program Director for the U.S. National Cancer Institute and oversaw a portfolio of health-related quality of life research in cancer patients. From 2010 to 2017, he served as Professor of Health Policy and Management at the University of North Carolina. From 2011-2013, Dr. Reeve served as President of the International Society for Quality of Life Research (ISOQOL). In 2015, he received the John Ware and Alvin Tarlov Career Achievement Prize in Patient-Reported Outcomes Measures. In 2017, 2018, 2019, 2021, 2022, and 2023, he was ranked in the top 1% most-cited in his respective field over the past 11-year period.

Jeff Yorio, MD
Texas Oncology

Dr. Yorio is a practicing hematologist and medical oncologist at Texas Oncology in Central Austin. He serves as the Central and South Texas Research Site Leader for Sarah Cannon Research Institute at Texas Oncology, and is on the executive board for Melanoma Research and Genitourinary Research for Sarah Cannon Research Institute. He also serves as the Chief of Hematology-Oncology at Ascension Seton Medical Center Austin.

NATIONAL ACADEMIES Sciences Engineering Medicine



National Cancer Policy Forum

The National Cancer Policy Forum serves as a trusted venue in which experts can identify emerging high-priority policy issues in cancer research and cancer care and work collaboratively to examine those issues through convening activities focused on opportunities for action. The forum provides a continual focus within the National Academies on cancer, addressing issues in science, clinical medicine, public health, and public policy that are relevant to the goal of reducing the cancer burden through prevention and by improving the care and outcomes for those diagnosed with cancer. Forum activities inform the cancer community and the public about critical policy issues through workshops and published reports. The forum has members with a broad range of expertise in cancer, including patient advocates, clinicians, and basic, translational, and clinical scientists. Forum members represent patients, federal agencies, academia, professional organizations, nonprofits, and industry.

The forum has addressed a wide array of topics, including

- enhancing collaborations to accelerate research and development;
- improving the quality and value of care for patients who have been diagnosed with or are at risk for cancer;
- developing tools and technologies to enhance cancer research and care; and
- examining factors that influence cancer incidence, mortality, and disparities.

NATIONAL CANCER POLICY FORUM

Upcoming and Recent Workshops

Policy Issues for Integrating Artificial Intelligence in Cancer Research and Care

Collaborative workshop convened by:
National Cancer Policy Forum
Computer Science and Telecommunications Board

March 9-10, 2026

The use of artificial intelligence (AI) in healthcare has been growing rapidly in recent years. It is increasingly recognized for its transformative potential in healthcare, particularly in oncology. This workshop will examine the current and potential future uses of AI in cancer care, and discuss ways to anticipate and address challenges related to the integration of these technologies in the care of patients with cancer. With a focus on the responsible and effective use of AI in oncology, the workshop will consider current policy initiatives across health care and the unique needs for oncology care.

Learn more and register here

Innovative Person-Centered Clinical Cancer Research

September 29-30, 2025

Person-centered clinical research can positively influence the outcomes of clinical research by providing a more accurate representation of real-world patient experiences. It addresses questions that are informed by patient experiences, needs, and perspectives, and involves patients in all stages of research, including design, activation, enrollment, data collection, completion, and outcome reporting. Although patient-reported outcome measures may offer potential benefits for clinical cancer research, challenges in the completeness, reliability, and validity of the data persist. This workshop will examine opportunities to overcome these challenges to advance the conduct of innovative, person-centered clinical cancer research to improve outcomes for all patients.

Learn more and register here

Strategies and Interventions to Strengthen Support for Family Caregiving and to Alleviate Caregiver Burden

Collaborative workshop convened by:
Roundtable on Quality Care for People with Serious Illness
National Cancer Policy Forum
Forum on Aging, Disability, and Independence

June 5-6, 2025

While unpaid, family caregivers can derive significant satisfaction and other positive benefits from caring for a loved one, research reveals that caregivers experience significant physical, psychological, emotional and financial burdens and a decline in their own physical and emotional health as a result of caring for people living with serious illness. This workshop discussed evidence-based interventions and strategies that effectively address the physical, mental, and financial challenges of caregiving.

Workshop videos and presentations *Proceedings-In-Brief*

Cancer Engineering: The Convergence of Engineering and Health to Advance Cancer Research and Care

Collaborative workshop convened by:
National Cancer Policy Forum
Board on Mathematical Sciences and Analytics
Board on Life Sciences

May 20-21, 2025

The concept of cancer engineering involves the application of engineering principles to solve challenges across cancer research and cancer care. This multidisciplinary approach brings together the fields of biology, engineering, and health care to devise innovative solutions that enhance the effectiveness, accessibility, and affordability of cancer care. This workshop considered opportunities to improve patient outcomes through the convergence of engineering with oncology practice, research, and policy.

Workshop videos and presentations

Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes

Collaborative workshop convened by:
National Cancer Policy Forum
Forum on Mental Health and Substance Use Disorders

March 17-18, 2025

The use of both alcohol and tobacco has independent and synergistic health effects, including links to many different cancers. There is a clear need to better understand the impact of dual use on cancer incidence and outcomes, to improve public education, and to develop oncology clinical practice guidelines for patients who use alcohol and tobacco. This workshop examined the current state of the science and explore strategies to reduce tobacco and alcohol use to lower cancer risk and improve health outcomes.

Workshop videos and presentations

Examining Clinical Guidelines for the Adoption of Genomic Testing

Collaborative workshop convened by:
Roundtable on Genomics and Precision Health
National Cancer Policy Forum

October 29, 2024

Clinical practice guidelines can impact adoption of new technologies into routine medical care. This workshop examined how guidelines for genomic testing are developed by various organizations, with a focus on exploring inconsistencies across guidelines and opportunities for a possible path forward for more consistent clinical guidelines for genomics to improve patient care.

Workshop videos and presentations *Proceedings-In-Brief*

Recent Workshops

Opportunities and Challenges for the Development and Adoption of Multicancer Detection Tests

October 28-29, 2024

Cancer screening is considered a key cancer control strategy because patients who are diagnosed with earlier stages of disease often have better treatment options and improved health outcomes. However, effective screening tests are lacking for most cancers. The development of minimally invasive approaches to screen for multiple tumor types at once could address this unmet need, but the clinical utility of multicancer detection (MCD) testing has yet to be established.

Workshop videos and presentations *Proceedings*

Enabling 21st Century Applications for Cancer Surveillance Through Enhanced Registries and Beyond

July 29–30, 2024

Population-based cancer surveillance has a pivotal role in assessing the nation's progress in cancer control. Cancer surveillance helps inform research and care interventions aimed at reducing the burden of cancer on patients and communities, including the ability to identify health disparities in cancer outcomes. Surveillance data are crucial for identifying emerging trends in health outcomes and opportunities to improve the quality of cancer care. However, challenges with the current approach to cancer surveillance in the United States include delays and gaps in data collection, as well as inadequate infrastructure and workforce to keep pace with the informatics and treatment-related advances in cancer. The National Cancer Policy Forum convened a public workshop to examine opportunities to enhance and modernize cancer surveillance in order to improve cancer research, care, and outcomes for all patients.

Workshop videos and presentations *Proceedings*

Toward a Framework to Improve Diversity and Inclusion in Clinical Trials

Collaborative workshop convened by:
Forum on Drug Discovery, Development, and Translation
National Cancer Policy Forum

May 20, 2024

This workshop aimed to explore opportunities to improve racial and ethnic diversity in clinical trials with a focus on system-level change and collective efforts across organizations and sectors that no one entity can effectively take on alone.

Workshop videos and presentations *Proceedings*

Biological Effectors of Social Determinants of Health in Cancer: Identi ication and Mitigation

March 20–21, 2024

Biological effectors of social determinants of health (SDOH) interact and impact cancer risk, treatment outcomes, and health equity. This workshop considered opportunities to advance health equity in cancer by identifying promising avenues for future research, as well as policies and interventions aimed at mitigating the negative impacts of the SDOH in cancer.

Workshop videos and presentations *Proceedings*

Optimizing Public–Private Partnerships for Clinical Cancer Research

Collaborative workshop convened by:
National Cancer Policy Forum
Forum on Drug Discovery, Development, and Translation

October 17–18, 2023

Public–private partnerships (PPPs) have the potential to more effectively leverage public funding and resources, increase the breadth and depth of research, and affect a more rapid translation from basic discoveries to public health applications. Industry, government, nonprofit, and academic organizations could each make important and unique contributions to this endeavor. This workshop examined opportunities to enhance and foster PPPsfor clinical cancer research and considered lessons learned from examples of public–private collaborations in oncology or other fields that have helped to advance clinical research and improve patient outcomes.

Workshop videos and presentations *Proceedings*

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care

Collaborative workshop co-hosted by:
National Cancer Policy Forum
American Society of Clinical Oncology

October 5–6, 2023

2023 marked the 10-year anniversary of the Institute of Medicine report *Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis* and the ability of the cancer care delivery system to provide high-quality cancer care to all patients remains elusive. This workshop provided an opportunity for the cancer care community to discuss persistent barriers to achieving excellent and equitable cancer care for all and additional actions that could be taken to implement the 2013 recommendations. Workshop presentations and discussions also identified aspects of cancer care that have changed over the past decade and where new strategies are needed to improve the quality of care.

Workshop videos and presentations *Proceedings*

Forum Sponsors

Centers for Disease Control and Prevention

National Institutes of Health/National Cancer Institute

American Association for Cancer Research

American Cancer Society

American College of Radiology

American Society of Clinical Oncology

Association of American Cancer Institutes

Association of Cancer Care Centers

AVEO Oncology

Cancer Center at Illinois

Flatiron Health

Lilly

Merck

National Comprehensive Cancer Network

Novartis Oncology

Oncology Nursing Society

Partners In Health

Patient Advocate Foundation

Pfizer Inc.

Forum Members

Robert A. Winn, M.D. (*Chair*)
Virginia Commonwealth University

Laleh Amiri-Kordestani. M.D.
U.S. Food and Drug Administration

Rohit Bhargava, Ph.D.
Cancer Center at Illinois

Smita Bhatia, M.D., M.P.H.
University of Alabama at Birmingham

Gideon Blumenthal, M.D.
Merck

Chris Boshoff, M.D., Ph.D.
Pfizer Inc.

Edgar E. Braendle, M.D., Ph.D.
AVEO Oncology

Christina Chapman, M.D.
Baylor College of Medicine

Gwen Darien, B.A.
Patient Advocate Foundation

Crystal Denlinger, M.D., FACP
National Comprehensive Cancer Network

James H. Doroshow, M.D.
National Cancer Institute

S. Gail Eckhardt, M.D., FASCO
Baylor College of Medicine

Christopher R. Friese, Ph.D., R.N., AOCN®
University of Michigan

Scarlett Lin Gomez, M.P.H., Ph.D.
University of California, San Francisco

Julie R. Gralow, M.D., FACP, FASCO
American Society of Clinical Oncology

Sarah M. Greene, M.P.H.
Cancer Research Advocate

Roy S. Herbst, M.D., Ph.D.
Yale University

Hedvig Hricak, M.D., Ph.D., Dr.h.c^{m}
Memorial Sloan Kettering Cancer Center

Chanita Hughes-Halbert, Ph.D.
University of Southern California

Roy A. Jensen, M.D.
University of Kansas; Association of American Cancer Institutes

Randy A. Jones, Ph.D., R.N., FAAN
University of Virginia

Beth Y. Karlan, M.D.
University of California, Los Angeles

Nancy L. Keating, M.D., M.P.H.
Georgetown University

Samir N. Khleif, M.D.
Georgetown University

Ronald Kline, M.D.
Centers for Medicare and Medicaid Services

Shivaani Kummar, M.D., FACP
Oregon Health and Science University

Elena Martinez, Ph.D.
University of California, San Diego

Larissa Nekhlyudov, M.D., M.P.H., FASCO
Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School

Cleo A. Ryals, Ph.D.
Flatiron Health

Susan M. Schneider, Ph.D., R.N., AOCN®
Duke University

Lawrence N. Shulman, M.D., MACP, FASCO
University of Pennsylvania

Michelle Sidel, Ph.D.
Novartis Pharmaceuticals

Amye J. Tevaarwerk, M.D.
Mayo Clinic in Rochester, Minnesota

Katrina Trivers, Ph.D., M.S.P.H.
Centers for Disease Control and Prevention

Megan Tweed, M.P.P
Lilly

Robin Yabroff, Ph.D.
American Cancer Society

Forum Staff

RESPONSIBLE STAFF OFFICERS

Francis Amankwah, M.P.H.
Forum Director

Sharyl Nass, Ph.D.
Senior Program Director, Health Care and Public Health

ADDITIONAL PROJECT STAFF

Anna Adler, M.P.H.
Research Associate

Torrie Brown, B.A.
Program Coordinator

Makeda Haughton, B.A.
Senior Program Assistant

Julie Wiltshire, B.S.
Senior Finance Business Partner

NATIONAL ACADEMIES *Sciences Engineering Medicine*

The National Academies provide independent, trustworthy advice that advances solutions to society's most complex challenges.
www.nationalacademies.org

CONTACT: Francis Amankwah ✉ famankwah@nas.edu
Board on Health Care Services
Health and Medicine Division

NATIONAL CANCER POLICY FORUM

WORKSHOP PROCEEDINGS AND RELATED PUBLICATIONS





WORKSHOP PROCEEDINGS

2025

Cancer Engineering: The Convergence of Engineering and Health to Advance Cancer Research and Care (In progress)

Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes (In progress)

Strategies and Interventions to Strengthen Support for Family Caregiving and to Alleviate Caregiver Burden

Opportunities and Challenges for the Development and Adoption of Multicancer Detection Tests

Exploring Clinical Guidelines for the Adoption of Genomic Testing

Enabling 21st Century Applications for Cancer Surveillance through Enhanced Registries and Beyond

2024

Toward a Framework to Improve Diversity and Inclusion in Clinical Trials

Biological Effectors of Social Determinants of Health in Cancer: Identification and Mitigation

Optimizing Public-Private Partnerships for Clinical Cancer Research

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care

Developing a Multidisciplinary and Multispecialty Workforce for Patients with Cancer, from Diagnosis to Survivorship

Incorporating Integrated Diagnostics into Precision Oncology Care

Addressing Treatment Resistance in the Development of Cancer Immune Modulator Therapeutics

2023

The Potential Contribution of Cancer Genomics Information to Community Investigations of Unusual Patterns of Cancer

Advancing Progress in Cancer Prevention and Risk Reduction

Realizing the Potential of Genomics across the Continuum of Precision Health Care

2022

Family Caregiving for People with Cancer and Other Serious Illnesses

Innovation in Electronic Health Records for Cancer Care, Research, and Surveillance

Promoting Health Equity in Cancer Care

The Role of Companion Animals as Sentinels for Predicting Environmental Exposure Effects on Aging and Cancer Susceptibility in Humans

Innovation in Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic:

Impact of the Affordable Care Act on Cancer Prevention and Cancer Care

To receive updates on the National Cancer Policy Forum, visit:

nationalacademies.org/NCPF

#NatlCancerForum

NATIONAL ACADEMIES Sciences Engineering Medicine





WORKSHOP PROCEEDINGS

2021

Addressing the Adverse Consequences of Cancer Treatment
Opportunities and Challenges for Using Digital Health Applications in Oncology
Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer
Advancing Progress in the Development and Implementation of Effective, High-Quality Cancer Screening
Drug Research and Development for Adults Across the Older Age Span

2020

Reflections on Sharing Clinical Trial Data: Challenges and a Way Forward
Applying Big Data to Address the Social Determinants of Health in Oncology
Health Literacy and Communication Strategies in Oncology
Enhancing Scientific Reproducibility in Biomedical Research Through Transparent Reporting

2019

Developing and Sustaining an Effective and Resilient Oncology Careforce
Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors
Improving Cancer Diagnosis and Care: Clinical Application of Computational Methods in Precision Oncology

2018

Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies
Establishing Effective Patient Navigation Programs in Oncology
Long-Term Survivorship Care After Cancer Treatment

2017

The Drug Development Paradigm in Oncology
Cancer Care in Low-Resource Areas: Cancer Treatment, Palliative Care, and Survivorship Care
Implementation of Lung Cancer Screening
Incorporating Weight Management and Physical Activity Throughout the Cancer Care Continuum

2016

Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment
Cancer Care in Low-Resource Areas: Cancer Prevention and Early Detection
Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology

2015

Comprehensive Cancer Care for Children and Their Families
Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies
Assessing and Improving the Interpretation of Breast Images
Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research

2014

Ensuring Patient Access to Affordable Cancer Drugs
Contemporary Issues for Protecting Patients in Cancer Research

2013

Identifying and Addressing the Needs of Adolescents and Young Adults with Cancer
Implementing a National Cancer Clinical Trials System for the 21st Century
Sharing Clinical Research Data
Delivering Affordable Cancer Care in the 21st Century
Reducing Tobacco-Related Cancer Incidence and Mortality









WORKSHOP PROCEEDINGS

2012

The Role of Obesity in Cancer Survival and Recurrence
Informatics Needs and Challenges in Cancer Research
Facilitating Collaborations to Develop Combination Investigational Cancer Therapies

2011

Implementing a National Cancer Clinical Trials System for the 21st Century
Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care
The National Cancer Policy Summit: Opportunities and Challenges in Cancer Research and Care
Nanotechnology and Oncology

2010

Direct-to-Consumer Genetic Testing (with the National Research Council)
Extending the Spectrum of Precompetitive Collaboration in Oncology Research
A Foundation for Evidence-Driven Practice: A Rapid Learning System for Cancer Care
Policy Issues in the Development of Personalized Medicine in Oncology

2009

Assessing and Improving Value in Cancer Care
Ensuring Quality Cancer Care Through the Oncology Workforce: Sustaining Care in the 21st Century
Multi-Center Phase III Clinical Trials and the NCI Cooperative Group Program

2008

Implementing Colorectal Cancer Screening
Improving the Quality of Cancer Clinical Trials

2007

Cancer-Related Genetic Testing and Counseling
Cancer in Elderly People
Implementing Cancer Survivorship Care Planning

2006

Effect of the HIPAA Privacy Rule on Health Research
Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment

RELATED WORK

CONSENSUS STUDY REPORTS BUILDING ON NCPF WORK

Childhood Cancer and Functional Impacts Across the Care Continuum (2021)
Report: nap.edu/catalog/25944

Diagnosing and Treating Adult Cancers and Associated Impairments (2021)
Report: nap.edu/catalog/25956

Guiding Cancer Control: A Path to Transformation (2019)
Report: nap.edu/catalog/25438

Making Medicines Affordable: A National Imperative (2017)
Report: nap.edu/catalog/24946

Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine (2016)
Report: nap.edu/catalog/21860

Ovarian Cancers: Evolving Paradigms in Research and Care (2016)
Report: nap.edu/catalog/21841

Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis (2013)
Report: nap.edu/catalog/18359

Evolution of Translational Omics: Lessons Learned and the Path Forward (2012)
Report: nap.edu/catalog/13297

A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program (2010)
Report: nap.edu/catalog/12879

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (2010)
Report: nap.edu/catalog/12869

Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research (2009)
Report: nap.edu/catalog/12458

Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment (2007)
Report: nap.edu/read/11892









INDIVIDUALLY AUTHORED PUBLICATIONS BUILDING ON NCPF WORK

Independent, individually authored articles arising from NCPF workshops—and consensus studies building on NCPF work—include:

2025

- Wagner, M., C. L. Benson, 2nd, S. Obeng-Gyasi, S. Conzen, L. E. McCullough, C. H. Halbert, and S. L. Gerson. 2025. Identifying and mitigating the biological effectors of the social determinants of health in cancer. *Journal of the National Cancer Institute*. https://doi.org/10.1093/jnci/djaf141.
- Shulman, L. N., H. Hricak, and S. G. Eckhardt. 2025. Challenges and opportunities for the US oncology workforce. *JAMA Oncology*. 10.1001/jamaoncol.2025.2331.
- Shulman, L. N., C. J. Bradley, R. A. Winn, and K. R. Yabroff. 2025. Cancer surveillance in the United States in jeopardy: Leveraging 21st century technology to enhance public health. *Journal of Clinical Oncology:JCO* 2500754.

2024

- Herbst, R. S., G. Blumenthal, S. N. Khleif, S. M. Lippman, N. J. Meropol, K. Rosati, L. N. Shulman, H. Smith, M. Wang, R. A. Winn, and R. L. Schilsky. 2024. Optimizing public private partnerships to support clinical cancer research. *Journal of the National Cancer Institute*. 10.1093/jnci/djae279
- Nekhlyudov, L., L. A. Levit, and P. A. Ganz. 2024. Delivering high-quality cancer care: Charting a new course for a system in crisis: One decade later. *Journal of Clinical Oncology*. 42(36):4342-4351.
- Peterson, D. E., N. L. Stout, L. N. Shulman, J. Perkins, G. LeMarier, and L. Nekhlyudov. 2024. Gaps in access to medically necessary dental care for patients living with and beyond cancer: We must do better. *Journal of Clinical Oncology*. https://doi.org/10.1200/JCO.24.00162.
- Singh, A. P., E. P. Balogh, R. W. Carlson, M. M. Huizinga, B. A. Malin, A. Melamed, N. J. Meropol, E. D. Pisano, R. A. Winn, K. R. Yabroff, and L. N. Shulman. 2024. Re-envisioning electronic health records to optimize patient-centered cancer care, quality, surveillance, and research. *Journal of Clinical Oncology: Oncology Practice*. 10.1200/OP.24.00260.

2022

- Bono, K. and N. L. Keating. 2022. Addressing social determinants of health: Now is the time. *Journal of the National Cancer Institute*. https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac137/6705076?searchresult=1.
- Bradley, C. J., S. Kitchen, S., Bhatia , J. Bynum, G. Darien, J. L. Lichtenfeld, R. Oyer, L. N. Shulman, and L. Kennedy Sheldon. 2022. Policies and practices to address cancer's long-term adverse consequences. *Journal of the National Cancer Institute*. 114(8):1065-1071. https://academic.oup.com/jnci/article-abstract/114/8/1065/6570605?redirectedFrom=fulltext.
- Davidson, N. E., K. E. Knudsen, S. Fuld Nasso, R. Oyer, S. Pergam, L. Strawbridge, and L. Shulman. 2022. Cancer care at the beginning of the COVID-19 pandemic: Effects on patients and early interventions to mitigate stresses on care. *Cancer Journal* 28(2):107-110. https://journals.lww.com/journalppo/Abstract/2022/03000/Cancer_Care_at_the_Beginning_of_the_

2022, continued

- Fan, Q, D. Keene, M. Banegas, S. Gehlert, L. M. Gottlieb, K. R. Yabroff, C. E . Pollack. 2022. Housing insecurity among patients with cancer. *Journal of the National Cancer Institute.* https://academic.oup.com/jnci/article/114/12/1584/6705075.
- Graboyes, E. M., K. H. Chaiyachati, J.S. Gall, W. Johnson, J. S. Krishnan, S. S. McManus, L. Thompson, L. N. Shulman, K. R. Yabroff. 2022. Addressing transportation insecurity among patients with cancer. *Journal of the National Cancer Institute.* https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac134/6705073?searchresult=1.
- Hyer, R. N. 2022. Insights for oncology trials garnered from the rapid development of an mRNA COVID-19 vaccine. *Cancer Journal* 28(2):146-150. https://journals.lww.com/journalppo/Fulltext/2022/03000/Insights_for_Oncology_Trials_Garnered_From_the.12.aspx.
- Karzai, F., and W. L. Dahut. 2022. Lessons from the impact of the COVID-19 pandemic at the national cancer institute: Cancer research and care. *Cancer Journal* 28(2):118-120. https://journals.lww.com/journalppo/Abstract/2022/03000/Lessons_From_the_Impact_of_the_COVID_19_Pandemic.7.aspx.
- Nekhlyudov, L., L. A. Fleisher, and P. B. Jacobsen. 2022. Telemedicine across the cancer care continuum: Evidence and opportunities for clinical care, research, and policy. *Cancer Journal* 28(2):121-124. https://journals.lww.com/journalppo/Abstract/2022/03000/Telemedicine_Across_the_Cancer_Care_Continuum_.8.aspx.
- Nekhlyudov L., G. B. Campbell., K. H. Schmitz, G.A. Brooks, A.J. Kumar, P.A. Ganz, and D. Von Ah 2022. Cancer-related impairments and functional limitations among long-term cancer survivors: Gaps and opportunities for clinical practice. *Cancer* 128(2): 222-229. https://pubmed.ncbi.nlm.nih.gov/34529268/.
- Oyer, R. A., L. Pierce, C. Lathan, and B. Sagar. 2022. Maintaining and advancing quality cancer care during a global pandemic. *Cancer Journal* 28(2):134-137. https://journals.lww.com/journalppo/Abstract/2022/03000/Maintaining_and_Advancing_Quality_Cancer_Care.10.aspx.
- Parikh, R. B., K. M. Basen-Engquist, C. Bradley, D. Estrin, M. Levy, J. L. Lichtenfeld, B. Malin, D. McGraw, N. J. Meropol, R. Oyer, L. Kennedy Sheldon, and L. N. Shulman. 2022. Digital health applications in oncology: An opportunity to seize. 2022. *Journal of the National Cancer Institute.*. https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djac108/6596055?redirectedFrom=fulltext#no-access-message.
- Prindiville, S. A., G. A. Sarosy, D. Loose, H. Ciolino, and J. H. Doroshow. 2022. Patterns of enrollment in cancer treatment trials during the COVID-19 pandemic at national cancer institute-designated cancer centers. *Cancer Journal* 28(2):111-117. https://journals.lww.com/journalppo/Abstract/2022/03000/Patterns_of_Enrollment_in_Cancer_Treatment_Trials.6.aspx.
- Raber, M., A. Jackson, K. Basen-Engquist, C. Bradley, S. Chambers, F. N. Gany, C. Hughes-Halbert, S. T. Lindau, R. Perez-Escamilla, and H. Seligman. 2022. Food insecurity among people with cancer: Nutritional needs as an essential component of care. *Journal of the National Cancer Institute.* https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac135/6705074?searchresult=1..
- Rivera, D. R., P. G. Kluetz, K. Abdallah, S. Agrawal, D. C. Angus, R. M. Califf, E. Garrett-Mayer, R. Hyer, D. R. Lowy, and S. N. Khleif. 2022. Clinical evidence generation during a pandemic: Lessons learned for sustaining progress. *Cancer Journal* 28(2):151-156. https://journals.lww.com/journalppo/Abstract/2022/03000/Clinical_Evidence_Generation_During_a_Pandemic_.13.aspx .
- Roberts, T. J., and I. T. Lennes. 2022. Lessons for oncology from the COVID-19 pandemic: Operationalizing and scaling virtual cancer care in health systems. *Cancer Journal* 28(2):125-133. https://journals.lww.com/journalppo/Abstract/2022/03000/Lessons_for_Oncology_From_the_COVID_19_Pandemic_.9.aspx.
- Schilsky, R. L. 2022. Beyond the COVID-19 pandemic: Sustaining and improving equitable cancer care and research. *Cancer Journal* 28(2):105-106. https://journals.lww.com/journalppo/Citation/2022/03000/Beyond_the_COVID_19_Pandemic__Sustaining_and.4.aspx.
- Winkfield, K. M., and R. A. Winn. 2022. Improving equity in cacer care in the face of a publice health emergency. Cancer Journal 28(2):128-145. https://journals.lww.com/journalppo/Abstract/2022/03000/Improving_Equity_in_Cancer_Care_in_the_Face_of_a.11.aspx

2021

- Bertagnolli, M. M. and H. Singh. 2021. Treatment of older adults with cancer - Addressing gaps in evidence. *New England Journal of Medicine* 385:1062-1065. https://www.nejm.org/doi/full/10.1056/NEJMp2106089.
- Housten, A. J., C. M. Gunn, M. K. Paasche-Orlow, and K. M. Basen-Engquist. 2021. Health literacy interventions in cancer: A systematic review. *Journal of Cancer Education* 36(2):240-252. https://pubmed.ncbi.nlm.nih.gov/33155097/.

2020

- Schilsky, R.L., S. Nass, M.M. Le Beau, and E. J. Benz, Jr. 2020. Progress in cancer research, prevention, and care. *New England Journal of Medicine* 383(10):897-990. https://www.nejm.org/doi/full/10.1056/NEJMp2007839..
- Shulman, L. N., L. Kennedy Sheldon, and E. J. Benz. 2020. The future of cancer care in the United States—Overcoming workforce capacity limitations. *JAMA Oncology* 6(3):327-328. https://jamanetwork.com/journals/jamaoncology/article-abstract/2758839..
- Panagiotou, O. A., L. Hoffman-Högg, H. Hricak, S. N. Khleif, M. A. Levy, D. Magnus, M. J. Murphy, B. Patel, R. A. Winn, S. J. Nass, C. Gatsonis, and C. R. Cogle. 2020. Clinical application of computational methods in precision oncology: A review. *JAMA Oncology* 6(8):1282:1286. https://jamanetwork.com/journals/jamaoncology/article-abstract/2765757..

2019

- Balogh, E. P., A. B. Bindman, S. G. Eckhardt, S. Halabi, R. D. Harvey, I. Jaiyesimi, R. Miksad, H. L. Moses, S. J. Nass, R. L. Schilsky, S. Sun, J. M. Torrente, and K. E. Warren. 2019. Challenges and opportunities to updating prescribing information for longstanding oncology drugs. *The Oncologist* 24:1-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066705/. .
- Takvorian, S. U., E. Balogh, S. Nass, V. L. Valentin, L. Hoffman-Högg, R. A. Oyer, R. W. Carlson, N. J. Meropol, L. Kennedy Sheldon, and L. N. Shulman. 2019. Developing and sustaining an effective and resilient oncology careforce: Opportunities for action, *Journal of the National Cancer Institute* 112(7):663-670. https://doi.org/10.1093/jnci/djz239 .
- Kline, R. M., G. B. Rocque, E. A. Rohan, K. A. Blackley, C. A. Cantril, M. L. Pratt-Chapman, H. A. Burris, and L.N Shulman. 2019. Patient navigation in cancer: The business case to support clinical needs. J*ournal of Oncology Practice* 15(11):585-590. https://www.ncbi.nlm.nih.gov/pubmed/31509483. .
- Lubejko, B. G., C. Cantril, L. H. Hogg, and L. Kennedy Sheldon. 2019. Novice oncology nurse navigator: Core elements in establishing training needs and building on competencies. *Clinical Journal of Oncology Nursing* 23(4):387-394. https://www.ncbi.nlm.nih.gov/pubmed/31322621. .

2019, continued

- Nass, S. J., M.B. Cohen, R. Nayar, M.M. Zutter, E. P. Balogh, R. L. Schilsky, H. Hricak, and K.S.J. Elenitoba-Johnson. 2019. Improving cancer diagnosis and care: Patient access to high-quality oncologic pathology. *The Oncologist* 24(10):1287-1290. https://www.ncbi.nlm.nih.gov/pubmed/31366725.
- Lopez, D., M. L. Pratt-Chapman, E. A. Rohan, L. Kennedy Sheldon, K. Basen-Engquist, R. Kline, L. N. Shulman, and E. J. Flores. 2019. Establishing effective patient navigation programs in oncology. *Supportive Care in Cancer* 27(6):1985-1996. https://www.ncbi.nlm.nih.gov/pubmed/30887125.
- Nass, S. J., C. R. Cogle, J. A. Brink, C. P. Langlotz, E. P. Balogh, A. Muellner, D. Siegal, R. L. Schilsky, and H. Hricak. 2019. Improving cancer diagnosis and care: Patient access to oncologic imaging expertise. J*ournal of Clinical Oncology* 37(20):1690-1694. https://www.ncbi.nlm.nih.gov/pubmed/31050908.

2018

- Kline, R. M., N. K. Arora, C. J. Bradley, E. R. Brauer, D. L. Graves, N. Buchanan Lunsford, M. S. McCabe, S. F. Nasso, L. Nekhlyudov, J. H. Rowland, R. M. Schear, and P. A. Ganz. Long-term survivorship care after cancer treatment—summary of a 2017 National Cancer Policy Forum workshop. *Journal of the National Cancer Institute* 110(12):1300-1310. https://www.ncbi.nlm.nih.gov/pubmed/30496448.
- Nass, S. J., M. Rothenberg, R. Pentz, H. Hricak, A. Abernethy, K. Anderson, A. W. Gee, R.D. Harvey, S. Piantadosi, M. M. Bertagnolli, D. Schrag, and R. L. Schilsky. Accelerating anticancer drug development—opportunities and trade-offs. *Nature Reviews Clinical Oncology* 15(12):777-786. https://www.ncbi.nlm.nih.gov/pubmed/30275514.
- Demark-Wahnefried, W., K. H. Schmitz, C. M. Alfano, J. R. Bail, P. J. Goodwin, C. A. Thomson, D. W. Bradley, K. S. Courneya, C. A. Befort, C. S. Denlinger, J. A. Ligibel, W. H. Dietz, M. R. Stolley, M. L. Irwin, M. M. Bamman, C. M. Apovian, B. M. Pinto, K. Y. Wolin, R. M. Ballard, A. J. Dannenberg, E. G. Eakin, M. M. Longjohn, S. D. Raffa, L. L. Adams-Campbell, J. S. Buzaglo, S. J. Nass, G. M. Massetti, E. P. Balogh, E. S. Kraft, A. K. Parekh, D. M. Sanghavi, G. S. Morris, and K. Basen-Engquist. 2018. Weight management and physical activity throughout the cancer care continuum. *CA: A Cancer Journal for Clinicians* 68(1):64-89. https://www.ncbi.nlm.nih.gov/pubmed/29165798.

2017

- Basen-Engquist, K., C. M. Alfano, M. Maitin-Shepard, C. A. Thomson, K. H. Schmitz, B. M. Pinto, K. Stein, D. S. Zucker, K. L. Syrjala, E. Fallon, C. Doyle, and W. Demark-Wahnefried. 2017. Agenda for translating physical activity, nutrition, and weight management interventions for cancer survivors into clinical and community practice. *Obesity* (Silver Spring) 25(Suppl 2):S9-S22. https://www.ncbi.nlm.nih.gov/pubmed/29086526.
- Smith, G. L., P. A. Ganz, J. E. Bekelman, S. J. Chmura, J. J. Dignam, J. A. Efstathiou, R. Jagsi, P. A. Johnstone, M. L. Steinberg, S. B. Williams, J. B. Yu, A. L. Zietman, R. R. Weichselbaum, and Y.-C. Shih. 2017. Promoting the appropriate use of advanced radiation technologies in oncology: Summary of a National Cancer Policy Forum workshop. *International Journal of Radiation Oncology • Biology • Physics* 97(3):450-461. https://www.ncbi.nlm.nih.gov/pubmed/28011046.

2016

- Kirch, R., G. Reaman, C. Feudtner, L. Wiener, L. A. Schwartz, L. Sung, and J. Wolfe. 2016. Advancing a comprehensive cancer care agenda for children and their families: Institute of Medicine workshop highlights and next steps. *CA: A Cancer Journal for Clinicians* 66(5):398-407. https://www.ncbi.nlm.nih.gov/pubmed/27145249.

2015

- Nass, S. J., L. K. Beaupin, W. Demark-Wahnefried, K. Fasciano, P. A. Ganz, B. Hayes-Lattin, M. M. Hudson, B. Nevidjon, K. C. Oeffinger, R. Rechis, L. C. Richardson, N. L. Seibel, and A. W. Smith. 2015. Identifying and addressing the needs of adolescents and young adults with cancer: Summary of an Institute of Medicine workshop. *Oncologist* 20(2):186-195. https://www.ncbi.nlm.nih.gov/pubmed/25568146.

2014

- Bertagnolli, M. M., R. Canetta, and S. J. Nass. 2014. Expanding public-private collaborations to enhance cancer drug development: A Report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century." *Oncologist* 19(11):1179-1185. https://www.ncbi.nlm.nih.gov/pubmed/25326161.
- Balogh, E. P., C. Dresler, M. E. Fleury, E. R. Gritz, T. J. Kean, M. L. Myers, S. J. Nass, B. Nevidjon, B. A. Toll, G. W. Warren, and R. S. Herbst. 2014. Reducing tobacco-related cancer incidence and mortality: Summary of an Institute of Medicine workshop. *Oncologist* 19(1):21-31. https://www.ncbi.nlm.nih.gov/pubmed/24304712.
- Ferrell, B. R., T. J. Smith, L. Levit, and E. Balogh. 2014. Improving the quality of cancer care: Implications for palliative care. *Journal of Palliative Medicine* 17(4):393-399. https://www.ncbi.nlm.nih.gov/pubmed/24548217.

2013

- Ramsey, S. D., P. A. Ganz, V. Shankaran, J. Peppercorn, and E. Emanuel. 2013. Addressing the American health-care cost crisis: Role of the oncology community. J*ournal of the National Cancer Institute* 105(23):1777-1781. https://www.ncbi.nlm.nih.gov/pubmed/24226096.
- Balogh, E. P., P. B. Bach, P. D. Eisenberg, P. A. Ganz, R. J. Green, J. C. Gruman, S. J. Nass, L. N. Newcomer, S. D. Ramsey, J. E. Schottinger, and Y. T. Shih. 2013. Practice-changing strategies to deliver affordable, high-quality cancer care: Summary of an Institute of Medicine workshop. *Journal of Oncology Practice* 9(6s):54s-59s. https://www.ncbi.nlm.nih.gov/pubmed/29431037.

Forum on
DRUG DISCOVERY, DEVELOPMENT,
and TRANSLATION

ABOUT THE FORUM

The Forum on Drug Discovery, Development, and Translation (the forum) of the National Academies of Sciences, Engineering, and Medicine (the National Academies) was created in 2005 by the National Academies Board on Health Sciences Policy to foster communication, collaboration, and action in a neutral setting on issues of mutual interest across the drug research and development lifecycle. The forum membership includes leadership from the National Institutes of Health, the U.S. Food and Drug Administration, industry, academia, consortia, foundations, journals, and patient groups.

Through the forum's activities, participants have been better able to bring attention and visibility to important issues, explore new approaches for resolving problem areas, share information and find common ground, and work together to develop ideas into concrete actions and new collaborations.

Forum work is based on four thematic priorities:

Spurring INNOVATION and IMPLEMENTATION

Revolutionary advances in biomedical research and technology present new and exciting opportunities for the discovery and development (R&D) of new therapies for patients. The evolution of health care is expanding possibilities for integration of clinical research into the continuum of clinical care and new approaches are enabling the collection of data in real-world settings. Innovative modalities, such as digital health technologies and artificial intelligence applications, can now be leveraged to overcome challenges and advance clinical research. The forum unites key stakeholders to identify opportunities, address bottlenecks, and spur innovation in drug discovery, development, and translation.

Increasing PERSON-CENTEREDNESS

There is much greater awareness around the need for more person-centered approaches that prioritize lived experience and justice in the discovery, development, and translation of new treatments. The forum seeks to center priorities of people living with disease and those who have been traditionally excluded from the clinical trials enterprise, advance the science of patient input, and help bring to fruition innovations that better address the needs of patients.

Promoting COLLABORATION and HARMONIZATION

The forum provides a neutral platform for communication and collaboration across sectors and disciplines to better harmonize efforts throughout the drug R&D life cycle. It does this by convening a broad and evolving set of stakeholders to help integrate patients, caregivers, researchers, trialists, community practitioners, sponsors, regulators, payers, patient groups, and others into the continuum of research and clinical care. The forum also strives to enable shared decision-making and ensure that patients have input into research questions, researchers have insight into clinical practice, and practitioners are engaged in the clinical trials enterprise.

Enhancing the WORKFORCE and INFRASTRUCTURE

The forum has fostered the development of strategies to improve the discipline of innovative regulatory science and continues to focus on building a workforce that is adaptable and resilient. Considerable opportunities remain to improve and expand the evolving clinical trials workforce and infrastructure, integrate community-based practices, and engage early-career scientists and clinicians in drug discovery, development, and translation. The forum will continue to anticipate and promote adaptation to changes in the infrastructure of health care delivery.

For more information about the Forum on Drug Discovery, Development, and Translation, please visit at:

NATIONALACADEMIES.ORG/DRUGFORUM

Health and Medicine Division
Board on Health Sciences Policy

NATIONAL ACADEMIES *Sciences Engineering Medicine*

Forum Membership

Forum Staff

Carolyn Shore, Ph.D.
Forum Director

Shalini Singaravelu, M.Sc.
Associate Program Officer

Noah Ontjes, M.A.
Associate Program Officer

Christa Nairn, M.P.H
Program Coordinator

NATIONAL ACADEMIES *Sciences Engineering Medicine*

Upcoming Workshop

Policy Issues for Integrating Artificial Intelligence in Cancer Research and Care: A Workshop
March 9-10, 2026

National Cancer Policy Forum in Collaboration with the Computer Science and Telecommunications Board

Keck Center Room 100
500 Fifth Street, NW
Washington, DC 20001

[Workshop Website]

Planning Committee: Samir Khleif and Amy Abernethy (Co-chairs), Crystal Denlinger, Usama Fayyad, Sarah Greene, Roy Herbst, Hedi Hricak, Chanita Hughes-Halbert, Beth Karlan, Cleo Ryals, Larry Shulman, and Rob Winn.

Workshop Statement of Task
A planning committee of the National Academies of Sciences, Engineering, and Medicine will organize and host a 1.5-day public workshop that will examine the current and potential future uses of Artificial Intelligence (AI) in cancer care, and ways to anticipate and address challenges related to integration of these technologies in the care of patients with cancer. With a focus on the responsible and effective use of AI in oncology, the workshop will consider current policy initiatives across healthcare and the unique needs for oncology care. Presentations and discussions at the workshop may include:

- **The current state and future applications of AI in oncology care:** the different types of AI and their application in current care and their future potential (e.g., AI biomarkers, treatment planning and clinical decision support systems, facilitating clinical efficiencies, product discovery, data curation, clinical evidence generation).
- **Existing policies and policy gaps** for rigorous and transparent assessment of data sets, training and validation, clinical validation, safety, and effectiveness of tools; for implementing new tools; and for monitoring use and performance, both for individual AI-based tools and within the global context of health care delivery.
- **Ethical and legal challenges such as** data security and patient privacy, algorithmic bias and drift, liability in AI-driven decisions, implications of autonomous decision-making tools, impact on access to care, transparency in the selection of training data, the models and objective functions used in training the data, code development and tool output, the role of AI in clinical decision-making for patients and clinicians, and intellectual property.
- **Potential future challenges such as** accuracy of AI output in the setting of rapidly changing evidence and clinical practice guidelines, increasing autonomy of AI systems, integration with other advanced technologies (e.g., genomics), and the need for adaptable policies that can evolve with rapid technological changes.
- **Ways to engage key participants** in dialogue and policy formulation, including patients, AI developers, healthcare providers, ethicists, legal experts, and industry leaders.
- **Data governance** for responsible use of patient data in AI systems, such as data anonymization, patient consent, data sharing practices, and accountability for data misuse.
- **Educational and training initiatives** on AI literacy to support effective utilization and interpretation of AI-generated insights by healthcare professionals, and to help patients understand how AI might influence their care.

The planning committee will develop the agenda for the workshop sessions, select and invite speakers and discussants, and moderate the discussions. A proceedings-in-brief of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.

Upcoming Workshop

Opportunities and Challenges in the Rising Incidence of Early-Onset Cancer: A Virtual Workshop

June 15-16, 2026

National Cancer Policy Forum

Keck Center Room 100
500 Fifth Street, NW
Washington, DC 20001

Workshop Website

Workshop Statement of Task

A National Academies of Sciences, Engineering, and Medicine planning committee will organize and host a virtual public workshop that will examine the rising incidence of cancer among adults younger than 50 years of age (early-onset cancers) and consider potential policies and practices to mitigate this trend and improve cancer care outcomes for this population. The workshop will feature invited presentations and panel discussions on topics that may include:

- The current state of knowledge on the epidemiology and biological basis of the rising incidence of early-onset cancers, and factors that may be contributing to current trends.
- Opportunities to increase awareness of the rising incidence and improve access to evidence-based preventive care services, including educational opportunities for health care providers.
- Potential strategies to reduce risk and improve early detection and diagnosis of early-onset cancers, including lessons learned from strategies to reduce the risk and incidence of cancer among the adolescent and young adult population.
- Opportunities to redesign cancer screening and treatment strategies based on the changing epidemiology.
- Implications for the health and social-related quality of life, treatment, and short- and long-term survivorship outcomes for those diagnosed with early onset cancers, including financial hardship, employment, and career trajectories.
- Implications for employers and worker benefits, including but not limited to health insurance coverage, paid leave, and workplace accommodations.
- Gaps in the evidence base and research, and potential strategies to address those gaps across the cancer continuum.

The planning committee will develop the agenda for the workshop sessions, select and invite speakers and discussants, and moderate the discussions. A proceedings-in-brief of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.

Planning Committee Pending

NATIONAL ACADEMIES *Sciences Engineering Medicine*

Preventing Discrimination, Harassment, and Bullying: Policy for Participants in National Academies Activities

Purpose

To prohibit discrimination, harassment, and bullying for all participants in National Academies activities.

Applicability

All participants in all settings and locations in which the National Academies work and activities are conducted.

Preventing Discrimination, Harassment, and Bullying: Policy for Participants in National Academies Activities

The National Academies of Sciences, Engineering, and Medicine (National Academies) are committed to the principles of integrity, civility, and respect in all of our activities. We look to you to be a partner in this commitment by helping us to maintain a professional and cordial environment. **All forms of discrimination, harassment, and bullying are prohibited in any National Academies activity.** This policy applies to all participants in all settings and locations in which the National Academies work and activities are conducted, including committee meetings, workshops, conferences, and other work and social functions where employees, volunteers, sponsors, vendors, or guests are present.

Definitions

Discrimination is prejudicial treatment of individuals or groups of people based on their race, color, national origin, sex, age, religion, disability, veteran status, or any other characteristic protected by applicable laws.
Sexual harassment is unwelcome sexual advances, requests for sexual favors, and other verbal or physical conduct of a sexual nature that creates an intimidating, hostile, or offensive environment.
Other types of harassment include any verbal or physical conduct directed at individuals or groups of people because of their race, ethnicity, color, national origin, sex, sexual orientation, gender identity, age, religion, disability, veteran status, or any other characteristic protected by applicable laws, that creates an intimidating, hostile, or offensive environment.
Bullying is unwelcome, aggressive behavior involving the use of influence, threat, intimidation, or coercion to dominate others in the professional environment.

Reporting and Resolution

Any violation of this policy should be reported. If you experience or witness discrimination, harassment, or bullying, you are encouraged to make your unease or disapproval known to the individual at the time the incident occurs, if you are comfortable doing so. You are also urged to report any incident by:

- Filing a complaint through the National Academies Complaint Intake Form (https://nas.hracuity.net/webform/index/a5ed0226-f5e5-4da4-be0d-1daf8976f594), and/or
- Filing a complaint with the Office of Human Resources at 202-334-3400 or hrservicecenter@nas.edu, or
- Reporting the incident to an employee involved in the activity in which the member or volunteer is participating, who will then file a complaint with the Office of Human Resources.

Complaints should be filed as soon as possible after an incident. To ensure the prompt and thorough investigation of the complaint, the complainant should provide as much information as is possible, such as names, dates, locations, and steps taken. The Office of Human Resources will investigate the alleged violation in consultation with the Office of the General Counsel.
If an investigation results in a finding that an individual has committed a violation, the National Academies will take the actions necessary to protect those involved in its activities from any future discrimination, harassment, or bullying, including in appropriate circumstances **the removal of an individual from current National Academies activities and a ban on participation in future activities**.

Confidentiality

Information contained in a complaint is kept confidential, and information is revealed only on a need-to-know basis. The National Academies will not retaliate or tolerate retaliation against anyone who makes a good faith report of discrimination, harassment, or bullying.

Responsible Party

The NRC Executive Officer is responsible for oversight of and substantive changes to the policy.

Revised: 01/28/2025